Cover Page  for Protocol  
Sponsor name:  [CONTACT_3454] A/S  
NCT number  [STUDY_ID_REMOVED]  
Sponsor t rial ID:  NN1436 -4478 
Official title of study:  A [ADDRESS_123989] and safety of once 
weekly  insulin icodec and once daily insulin degludec, both 
with or  without non -insulin anti -diabetic drugs, in subjects 
with type 2  diabetes treated with basal insulin (ONWARDS 2)  
Document date *: 14 April  2021  
 
*Document date refers to the date on which the document was most recently updated.  
 
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  1 of 100 
 
Protocol  
 
Protocol title:  A [ADDRESS_123990] and safety of once weekly insulin icodec 
and once daily insulin degludec, both with or without non- insulin anti -diabetic drugs, in 
subjects with type 2 diabetes treated with basal insulin  
ONWARDS 2 
Substance: Insulin icodec  
Universal Trial Number: U1111 -[ADDRESS_123991] Number: 2020 -000454 -10  
IND Number: 137406 
 
 Trial phase:  3a 
 
 
 
 
 
 
 In the following, Novo Nordisk A/S and its affiliates will be stated as “Novo Nordisk”.  
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.  
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
 
 
 
 
 
Redacted protocol  
Includes redaction of personal identifiable information only.  
 
 
 
. 
 
 
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  2 of 100 
 
Protocol amendment summary of changes table  
DOCUMENT HISTORY  
Document version  Date  Applicable in country( -ies) and/or 
site(s)  
Protocol version 3.0  14 April  2021  All countries  
Protocol version 2.0 30 November 2020  All countries  
Original protocol version 1.0  02 July 2020  All countries  
 
Protocol version 3.0 (14 Ap ril 2021) 
This amendment is considered to be non-substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union1, because 
it neither significantly impacts the safety nor physical/mental integrity of subjects nor the scientific 
value of the trial.  
Overall rationale for preparing protocol, version 3.0: 
The protocol has been amended to correct typos and exclude Japan  and [LOCATION_013]  from 
co-participat ion in clinical trials evaluating medicinal products for prevention or treatment of 
COVID-[ADDRESS_123992]. 
Section # and name  [CONTACT_111444]  
8.2.2 Physical examinations  “the BMI will be calculated in the 
eCRF ” is corrected to “the BMI 
should be calculated and  recorded in 
subject’s medical records”  Correction  
10.6 Appendix 6: Retention of human 
biosamples  “In case of a systematic 
hypersensitivity reaction ” is corrected 
to “In case of a systemic 
hypersensitivity reaction ” Correction of typo  
10.8 Appendix 8 Titration guideline  Table for V2 and V3 weekly dose:  
For “ Total daily dose before 
randomisation (U) : 82 “ 
“V2 insulin icodec dose (U) ”: 960 is 
corrected to 860  Correction of typo  
10.9 Appendix 9: Country/Region -
specific requirements  Footnotes related  to co-participation 
in clinical trial for COVID -[ADDRESS_123993].  
 
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  3 of 100 
 
Section # and name  [CONTACT_111444]  
10.[ADDRESS_123994] 
version 2.0  Reference  update s 
 
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  4 of 100 
 
Table of Contents    
 Page 
Protocol a mendment  summary of changes table  ........................................................................................... 2 
Table of Contents .............................................................................................................................................. 4 
1 Protocol summary  ..................................................................................................................................... 8 
1.1 Synopsis ........................................................................................................................................... 8 
1.2 Flowchart ....................................................................................................................................... 11 
1.3 Flowchart – phon e contacts  ........................................................................................................... 14 
2 Introduction  ............................................................................................................................................. 15 
2.1 Trial rationale  ................................................................................................................................. 15 
2.2 Background .................................................................................................................................... 16 
2.3 Benefit -risk assessment  .................................................................................................................. 17 
2.3.1  Risk assessment  ............................................................................................................... 17 
2.3.2  Benefit assessment  ........................................................................................................... 20 
2.3.3  Overall benefit -risk conclusion ....................................................................................... 20 
3 Objectives and endpoints  ........................................................................................................................ 21 
3.1 Primary, secondary and exploratory objective and estimand......................................................... 21 
3.1.1  Primary objective  ............................................................................................................. 21 
3.1.2  Secondary objective ......................................................................................................... 21 
3.1.3  Estimand  .......................................................................................................................... 21 
3.2 Primary, secondary and exploratory endpoints .............................................................................. 21 
3.2.1  Primary endpoint ............................................................................................................. 21 
3.2.2  Seco ndary endpoints ........................................................................................................ 21 
[IP_ADDRESS]  Confirmatory secondary endpoints ................................................................. 21 
[IP_ADDRESS]  Supportive secondary endpoints  ..................................................................... [ADDRESS_123995] input into design  ................................................................................................. 25 
4.3 Justification for dose ...................................................................................................................... 25 
4.4 End of trial definition  ..................................................................................................................... 26 
5 Trial population ....................................................................................................................................... 26 
5.1 Inclusion criteria ............................................................................................................................ 26 
5.2 Exclus ion criteria  ........................................................................................................................... 27 
5.3 Lifestyle considerations  ................................................................................................................. 28 
5.3.1  Meals and dietary restrictions .......................................................................................... 28 
5.3.2  Caffeine, alcohol and tobacco ......................................................................................... 28 
5.3.3  Physical activity ............................................................................................................... 28 
5.4 Screen failures ................................................................................................................................ 28 
5.5 Run-in criteria, randomisation criteria and dosing day criteria...................................................... 29 
6 Treatments  ............................................................................................................................................... 29 
6.1 Treatments administered  ................................................................................................................ 29 
6.1.1  Medical devices  ............................................................................................................... 30 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  5 of 100 
 
[IP_ADDRESS]  Investigational medical device  ........................................................................ 30 
[IP_ADDRESS]  Non-investigational medical devices  .............................................................. 30 
6.2 Preparation/handling/storage/accountability  .................................................................................. 31 
6.3 Measures to minimise bias: Randomisation and blinding ............................................................. [ADDRESS_123996] discontinuation/withdrawal  ..................................... [ADDRESS_123997] discontinuation/withdrawal from the trial ......................................................................... [ADDRESS_123998] to follow -up ........................................................................................................................... 36 
8 Trial assessments and procedures  ......................................................................................................... 36 
8.1 Efficacy assessments  ...................................................................................................................... 37 
8.1.1  Self-measured plasma glucose (SMPG)  .......................................................................... 38 
8.1.2  Continuous glucose monitoring  ....................................................................................... 38 
8.1.3  Clinical outcome assessments  ......................................................................................... 39 
8.1.4  Clinical efficacy la boratory assessments  ......................................................................... 39 
8.2 Safety assessments  ......................................................................................................................... 39 
8.2.1  Insulin dose  ...................................................................................................................... 40 
8.2.2  Physical  examinations ..................................................................................................... 40 
8.2.3  Vital signs  ........................................................................................................................ 41 
8.2.4  Electrocardiograms  .......................................................................................................... 42  
8.2.5  Eye
 examination .............................................................................................................. 42 
8.2.6  Clinical safety laboratory assessments  ............................................................................ 43 
8.3 Adverse events and serious adverse events  .................................................................................... 43 
8.3.1  Time period and frequency for collecting AE and SAE information .............................. 45 
8.3.2  Method of detecting AEs and SAEs ................................................................................ 45 
8.3.3  Follow-up of AEs and SAEs ........................................................................................... 45 
8.3.4  Regulatory reporting requirements for SAEs .................................................................. 45 
8.3.5  Pregnancy ........................................................................................................................ 46 
8.3.6  Cardiovascular and death events ..................................................................................... 46 
8.3.7  Disease- related events and/or disease-related outcomes not qualifying as an AE or 
SAE  ................................................................................................................................. 46 
8.3.8  Adverse event of special interesta .................................................................................... 46 
8.3.9  Technical complaints  ....................................................................................................... 46 
8.4 Treatment of overdose  ................................................................................................................... 47 
8.5 Pharmacokinetics  ........................................................................................................................... 47 
8.6 Pharmaco dynamics ........................................................................................................................ 48 
8.7 Genetics  ......................................................................................................................................... 48 
8.8 Biomarkers ..................................................................................................................................... 48 
8.9 Immunogenicity assessments  ......................................................................................................... 48 
8.9.1  Anti-drug antibodies ........................................................................................................ 48 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  6 of 100 
 
8.9.2  Hypersensitivity ............................................................................................................... 49 
8.10  Healt h economics ........................................................................................................................... 49 
9 Statistical considerations  ........................................................................................................................ 50 
9.1 Statistical hypotheses  ..................................................................................................................... 50 
9.2 Sample size determination  ............................................................................................................. 51 
9.3 Populations for analyses  ................................................................................................................ 52 
9.4 Statistical analyses  ......................................................................................................................... 53 
9.4.1  General considerations .................................................................................................... 53 
9.4.2  Primary endpoint ............................................................................................................. 53 
9.4.3  Seco ndary endpoints ........................................................................................................ 55 
[IP_ADDRESS]  Confirmatory secondary endpoint ................................................................... 55 
[IP_ADDRESS]  Supportive secondary endpoints  ..................................................................... 55 
9.4.4  Exploratory endpoints  ..................................................................................................... 57 
9.4.5  Other safety analyses  ....................................................................................................... 57 
9.4.6  Other analyses  ................................................................................................................. 57 
[IP_ADDRESS]  Pharmacokinetic modelling  ............................................................................. 57 
9.5 Interim analyses  ............................................................................................................................. 58 
9.6 Data mon itoring committee  ........................................................................................................... 58 
9.7 Reporting of the main part of the trial ............................................................................................ 58 
10 Supporting documentation and operational considerations  ............................................................... 59 
10.1  Appendix 1: Regulatory, ethical, and trial oversight considerations ............................................. 59 
10.1.1  Regulatory and ethical considerations  ............................................................................. 59 
10.1.2  Financial disclosure  ......................................................................................................... 59 
10.1.3  Informed consent process  ................................................................................................ 60 
10.1.4  Information to subjects during trial ................................................................................. 60 
10.1.5  Data protection  ................................................................................................................ 60 
10.1.6  Committees structure  ....................................................................................................... 61 
[IP_ADDRESS]  Novo Nordisk safety committee...................................................................... 61  
[IP_ADDRESS]  Trial
 safety group  ............................................................................................ 61 
[IP_ADDRESS]  Data monitoring committee ............................................................................. 61 
[IP_ADDRESS]  Event adjudication committee  ......................................................................... 61 
10.1.7  Dissemination of clinical trial data  .................................................................................. 61 
10.1.8  Data quality assurance  ..................................................................................................... 62 
[IP_ADDRESS]  Case report forms  ............................................................................................ 62 
[IP_ADDRESS]  Monitoring ...................................................................................................... 62 
[IP_ADDRESS]  Proto col compliance  ........................................................................................ 63 
10.1.9  Source documents ............................................................................................................ 63 
10.1.10  Retention of clinical trial documentation  ........................................................................ 64 
10.1.11  Trial and site closure  ....................................................................................................... 64 
10.1.12  Responsibilities ................................................................................................................ 65 
10.1.13  Indemnity statement  ........................................................................................................ 65 
10.1.14  Publication policy  ............................................................................................................ 66 
[IP_ADDRESS]  Communication of results  ............................................................................... 66 
[IP_ADDRESS]  Authorship ....................................................................................................... 67 
[IP_ADDRESS]  Site-specific publication(s) by [CONTACT_1697](s)................................................. 67 
[IP_ADDRESS]  Investigator access to data and review of results  ............................................ 67 
10.2  Appendix 2: Clinical laboratory tests  ............................................................................................ 68 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  7 of 100 
 
10.3  Appendix 3: Adverse events: Definitions and procedures for recording, evaluation, follow-
up, and reporting  ............................................................................................................................ 70 
10.3.1  Definition of AE  .............................................................................................................. 70 
10.3.2  Definition of an SAE  ....................................................................................................... 71 
10.3.3  Description of events for adjudication and AEs requiring additional data collection ..... 72 
10.3.4  Recording and follow -up of AE and/or SAE ................................................................... 74 
10.3.5  Reporting of SAEs  ........................................................................................................... 76 
10.4  Appendix 4: Contraceptive guidance and collection of pregnancy inform ation  ............................ 78 
10.5  Appendix 5: Technical complaints: Definition and procedures for recording, evaluation, 
follow- up and reporting  ................................................................................................................. 81 
10.5.1  Definition of technical complaint  .................................................................................... 81 
10.5.2  Recording and follow -up of technical complaints ........................................................... 81 
10.5.3  Reporting of technical complaints  ................................................................................... 82 
10.6  Appendix 6: Retention of human biosamples ................................................................................ 83 
10.7  Appendix 7: Hypoglycaemic epi[INVESTIGATOR_1841] ........................................................................................... 84 
10.8  Appendix 8: Titration guideline ..................................................................................................... 86 
10.9  Appendix 9: Country- specific requirements  .................................................................................. 90 
10.10  Appendix 10: Abbreviations .......................................................................................................... 93 
10.11  Appendix 11: Protocol amendment history ................................................................................... [ADDRESS_123999] of key staff and relevant departments . 
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  8 of 100 
 
1 Protocol summary  
1.1 Synopsis  
Rationale: 
Insulin icodec is a novel long-acting insulin analogue which is developed to safely cover the basal 
insulin requirements for a full week with a single subcutaneous injection.  The present trial is a [ADDRESS_124000] and safety of once weekly insulin icodec in comparison to once daily insulin degludec, both with or without non-insulin anti-diabetic drugs, in basal insulin 
treated subjects with type 2 diabetes ( T2D). 
Objectives and endpoints:  
Primary objective 
The objective of this trial is to demonstrate the effect on glycaemic control of once weekly insulin 
icodec, with or without non-insulin anti-diabetic drugs, in subjects with T2D treated with basal insulin. This includes comparing the difference in change from baseline in HbA
1c between insulin 
icodec and insulin degludec after 26 weeks of treatment to a non- inferiority limit of 0.3%.  
Estimand 
The estimand is the ‘treatment policy estimand’  defined as the treatment difference between insulin 
icodec and insulin degludec of the change in HbA 1c from baseline to week 26 for all randomised 
subjects, irrespective of adherence to randomised treatment and changes to anti-diabetic background medicati on. The following intercurrent events will be handled by [CONTACT_17983]: 
initiation of bolus insulin treatment for more than 2 weeks, discontinuation of randomised insulin treatment, and withdrawal from the trial (measurements collected afte r these intercurrent events are 
used in the primary analysis). 
Primary endpoint  
Endpoint title  Time frame  Unit  
Change in HbA 1c From baseline week 0 (V2) to week 26 (V28)  %-point  
Overall design:  
This is a 26-week randomised, open label, active-controlled, parallel-group, multicentre, 
multinational, treat- to-target trial with two treatment arms.  
Subjects will be randomised (1:1) to receive once weekly insulin icodec or once daily insulin 
degludec. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  9 of 100 
 
Key inclusion criteria : 
1. Male or female aged above or equal to 18 years at the time of signing informed consent. 
2. Diagnosed with T2D ≥ 180 days prior to the day of screening. 
3. HbA 1c from 7.0-10.0% (53.0-85.8 mmol/mol) both inclusive at screening confirmed by [CONTACT_111392]. 
4. Treated with once daily or twice daily basal insulin (Neutral Protamine Hagedorn insulin, 
insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 
units/mL) : ≥ 90 days prior to the day of screening with or without any of the following anti-
diabetic drugs/regimens with stable doses ≥ 90 days prior to screening:  
• Metformin  
• Sulfonylureas 
• Meglitinides (glinides)  
• DPP-4 inhibitors 
• SGLT2 inhibitors 
• Thiazolidinediones 
• Alpha-glucosidase inhibitors 
• Oral combination products (for the allowed individual oral anti-diabetic 
drugs) 
• Oral or injectable GLP -1-receptor agonists 
5. Body mass index (BMI) ≤ 40.0 kg/m2. 
Key exclusion criteria : 
1. Any epi[INVESTIGATOR_111342] 90 days prior to the day of screening. 
2. Myocardial infarction, stroke, hospi[INVESTIGATOR_41070] 180 days prior to the day of screening. 
3. Chronic heart failure classified as being in [LOCATION_001] Heart Association Class IV at screening. 
4. Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) 
known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or 
corticosteroids). 
5. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past [ADDRESS_124001] or in the medical records.  
Number of subjects:  
Approximately [ADDRESS_124002]. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  10 of 100 
 
Treatment groups and duration:  
The trial duration is approximately [ADDRESS_124003] will be centrally 
randomised in a 1:[ADDRESS_124004] at the discretion of the investigator. 
The following trial products will be supplied by [CONTACT_111393]: 
• Insulin icodec 700 units/mL, subcutaneous, solution for injection, 3 mL PDS290 pre- filled 
pen-injector  
• Insulin degludec 100 units/mL, subcutaneous, solution for injection, 3 mL PDS290 pre- filled 
pen-injector . 
Data monitoring committee: No  
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol        Date:  14 April 2021  Status:  Final  Novo Nordisk  
Trial ID: NN1436 -4478        Version:  3.0 Page:  [ADDRESS_124005] 
number (P) (For details see 
separate flowchart  in 1.3)       P7 P9 
P10 
P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23         
Timing of visit (weeks)   ≤-2 0 1 2 3 4 6 10 14 18 22 23 24 25 26 28 31 26 
Visit window (days)     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 
Informed consent and 
demography  App. 1; 
10.1 X                  
Tobacco use  5.3.2  X                  
Eligibility Criteria  5.1, 5.2  X X                 
Attend visit fasting  5.3.1   X      X  X     X    
Concomitant illness/medical 
history  8.2 X X                 
Concomitant medication  6.5 X X X X X X X X X X X X X X X X X X 
Vital signs  8.2.3  X        X      X    
Physical examination  8.2.2  X              X    
Body measurements  8.2.2  X X       X      X   X 
Eye examination  8.2.5  X              X    
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol        Date:  14 April 2021  Status:  Final  Novo Nordisk  
Trial ID: NN1436 -4478        Version:  3.0 Page:  [ADDRESS_124006] 
number (P) (For details see 
separate flowchart  in 1.3)       P7 P9 
P10 
P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23         
Timing of visit (weeks)   ≤-2 0 1 2 3 4 6 10 14 18 22 23 24 25 26 28 31 26 
Visit window (days)     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±[ADDRESS_124007]  8.3.5 , 
App. 4; 
10.4  X             X  X  
Laboratory assessments  App.2 ; 
10.2 X X  X   X X  X     X  X X 
HbA1c   X X      X  X     X   X 
Pop-PK (insulin icodec serum 
concentration)  8.5    X   X X  X     X  X  
Antibodies  (anti-insulin 
icodec antibodies ) 8.9.1   X  X   X X  X     X  X  
Self-measured plasma 
glucose  8.1.1   X X X X X X X X X X X X X X X X  
Adverse event  8.3 
App. 3; 
10.3   X X X X X X X X X X X X X X X X 
Hypoglycaemic epi[INVESTIGATOR_111343]. 7; 
10.7   X X X X X X X X X X X X X X X  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol        Date:  14 April 2021  Status:  Final  Novo Nordisk  
Trial ID: NN1436 -4478        Version:  3.0 Page:  [ADDRESS_124008] 
number (P) (For details see 
separate flowchart  in 1.3)       P7 P9 
P10 
P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23         
Timing of visit (weeks)   ≤-2 0 1 2 3 4 6 10 14 18 22 23 24 25 26 28 31 26 
Visit window (days)     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±[ADDRESS_124009] in devices  6  X                 
End of trial  4.4                 X X 
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol        Date:  14 April 2021  Status:  Final  Novo Nordisk  
Trial ID: NN1436 -4478        Version:  3.0 Page:  14 of 100 
 
1.3 Flowchart – phone contacts  
Phone contacts during the treatment period (P)  
Time shown in site visit flow chart  Protocol 
section  P7-P23 
Visit window (days)   ±3 
Concomitant medication  6.5 X 
Self-measured plasma glucose  8.1.1  X 
Adverse event  8.3 
App. 3: 10.3 X 
Hypoglycaemic epi[INVESTIGATOR_111343]. 7; 10.7 X 
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  15 of 100 
 
2 Introduction 
Diabetes mellitus is a metabolic disorder characterised by [CONTACT_41125], insulin action or both. The chronic hyperglycaemia of diabetes mellitus 
is associated with significant long -term complications, particularly damage, dysfunction and failure 
of various tissues – especially the kidney, eye, nerves, heart and blood vessels .2 Diabetes is 
generally classified according to aetiological factors, where type 1 diabetes (T1D) and type 2 
diabetes (T2D) constitute the vast majority of cases. In the latest edition of the International 
Diabetes Federation’s Diabetes Atlas (2019), the estimated worldwide diabetes prevalence was [ADDRESS_124010] increased to 700 million.
3  
Insulin icodec (proposed INN) is a novel long-acting insulin analogue which is developed to safely cover the basal insulin requirements for a full week with a single subcutaneous injection. Insulin 
icodec has a terminal elimination half -life of approximately [ADDRESS_124011] and safety of once weekly insulin 
icodec in comparison to once daily insulin degludec 100 units/mL (referred to as insulin degludec in 
this document), both with or without non-insulin anti-diabetic drugs, in basal insulin treated 
subjects with T2D.  
The long-acting basal insulin products currently approved for treatment of diabetes are administered 
once or twice daily. Development of sustained release formulations or compounds with prolonged 
action has in several treatment areas been demonstrated to improve subject compliance and 
treatment outcomes. The once weekly treatment regimen for insulin icodec is expected to represent 
a more convenient basal insulin, with significantly fewer injectio ns over time, which could improve 
treatment adherence4 as compared to once daily or twice daily basal insulin for subjects with T2D. 
Overall, the results of t he present trial will be important for evaluating the effect and safety of 
insulin icodec in insulin experienced subjects with T2D and will be used to support the marketing authorisation approval of insulin icodec. The trial will also generate data for guidance on transfer 
from once or twice daily basal insulin to once weekly insulin icodec, data on dosing flexibility, 
treatment satisfaction, and insulin preference.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  16 of 100 
 
2.2 Background 
Diabetes mellitus  
T2D is characterised by [CONTACT_30361], impaired insulin s ecretion, increased hepatic glucose 
output due to glucagon dysregulation resulting in chronic hyperglycaemia.5 The pathogenesis is not 
fully understood but seems to be heterogeneous, involving environmental, lifestyle, and genetic 
factors leading to chronic hyperglycaemia caused by [CONTACT_111394], impaired 
insulin secretion due to abnormal be ta-cell function and abnormal glucose metabolism in the liver.6 
The current treatment cascade follows a stepwise approach comprising lifestyle changes in combination with pharmacological intervention. In many countries, metformin is recommended as 
initial pharmacological therapy, followed by [CONTACT_111395]- diabetic 
drugs, glucagon-like peptide 1 receptor agonists (GLP -1 RA ) and/or insulin as the disease 
progresses.
[ADDRESS_124012] s require a new intervention 
with glucose-lowering agents every 3-4 years in order to obtain/retain good glycaemic control.[ADDRESS_124013] s with T2D who are not achieving recommended glycaemic targets.9, 10 
Increased conv enience is believed to support timely insulin initiation in the treatment for T2D and 
thereby [CONTACT_111396].  
Insulin icodec  
Insulin icodec is a novel long-acting insulin analogue which is developed to s afely cover the basal 
insulin requirements for a full week with a single subcutaneous injection. Insulin icodec has a terminal elimination half -life of approximately 196 hours. The molecule consists of a peptide 
backbone and a fatty acid -containing side- chain. The peptide backbone is more resistant towards 
proteolytical degradation compared to human insulin and the side chain gives a strong binding to 
albumin. Both features contribute to the long action of insulin icodec.  
The development programme for insulin icodec is currently ongoing. Three clinical pharmacology 
trials, NN1436-4314 [T2D], NN1436-4226 [renal impaired] and NN1436-4422 [T1D] have been 
completed. No unexpected  safety concerns were identified. Two clinical pharmacology trials 
(NN1436-4462 [T2D] and NN1436-4225 [T1D]) are ongoing.  
Three phase [ADDRESS_124014] recently been completed (NN1436-4465, NN1436-
4383 and NN1436-4466). Once weekly insulin icodec was shown to provide comparable glucose 
lowering effects and similar safety  profile to insulin glargine in subjects with T2D. Results from 
these trials were used in the development of the insulin icodec titration guideline, see Appendix 8 (Section 10.8
). 
A comprehensive review of results from the non- clinical and clinical studies of insulin icodec can 
be found in the current edition of the investigator’s brochure11 and any updates hereof.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  17 of 100 
 
Insulin degludec  
For further details on insulin degludec, please refer to the current insulin degludec investigator’s 
brochure12, the current EMA summary of product characteristics for insulin degludec (Tresiba®)13, 
the US prescr ibing information14, or any locally approved label. 
Trial population 
The trial population will consist of basal insulin treated subjects with T2D. Subjects included in the 
trial will already be on basal insulin analogue treatment with or without non -insulin anti- diabetic 
drugs ensuring a trial population representative of a broad T2D population. 
Subjects with T1D are excluded from this trial. Subjects with T1D will be addressed in a dedicated 
trial. 
For more information on the trial population, see Section 4.[ADDRESS_124015] the 
possibility of a causal relationship with insulin icodec, but where there is currently insufficient evidence to conclude that this association is causal.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  18 of 100 
 
Identified/Potential risk of 
clinical significance  Summ ary of data/  
rationale for risk  Mitigation strategy  
Trial treatment: insulin icodec  
Identified risk:  
Hypoglycemia  Hypoglycemia is an 
anticipated undesirable 
effect related to the pharmacological mechanism of insulin. Exclusion criteria in clinical trials with subjects at 
increased risk of hypoglycaemia:  
• Known hypoglycaemic unawareness as indicated 
by [CONTACT_111397]’s 
questionnaire question 8 (Section 5.2), 
• Recurrent severe hypoglycaemic epi[INVESTIGATOR_111344].  
Frequent blood glucose measurements will be made throughout drug exposure and will prevent worsening of hypoglycaemia by [CONTACT_111398], 
if necessary.  
The risk of hypoglycaemia is addressed in the SI -IC 
and IB
11. Subject s are provided with a guidance on 
hypoglycaemia awareness and rescue actions.  
Identified risk:  
Injection site reactions  Injection site reactions 
may occur with all 
injectable drugs. Injection site reactions were 
reported in trials NN1436 -
4422, NN1436- 4383, 
NN1436- 4465, NN1436-
4466, NN1436- 4226. All 
were mild and resolved during continued treatment 
with insulin icodec.  Subjects are instructed by [CONTACT_111399].  
Recommendations on rotation of the site of injection are included in the trial protocol and SI -IC.  
Investigators and subjects will be instructed to monitor for injection site reactions at the place of injection for early detection. Investigators should ensure careful monitoring and medical evaluation in case of injection 
site reaction occurrence. The risk of injection site 
reactions is described in the IB
11 and the SI -IC. 
For further information on injection site reactions, 
please refer to Appendix 3 (Section 10.3.3 ). 
Potential risk:  
Hypersensitivity  Severe systemic 
hypersensitivity reactions 
may potentially occur following injection of therapeutic proteins. No systemic hypersensitivity reactions were observed in 
trials NN1436 -4314, 
NN1436- 4383, NN1436-
4465, NN1436- 4466, 
NN1436- [ADDRESS_124016](s) 
or related products is an exclusion criterion in the 
clinical trial.  
Subjects and investigators will be instructed in signs and symptoms of hypersensitivity reactions and subjects will be instructed to contact [CONTACT_111400].  
Blood sampling for assessment of antibodies against insulin icodec, as well as other assessments will be conducted in the case of systemic hypersensitivity 
reaction. Confirmed a nti-insulin icodec antibody 
positive samples will have an antibody titer value 
determined and will be further tested for cross -
reactivity to endogenous insulin.  
The risk of hypersensitivity reactions is described in 
the IB
11 and SI -IC.   
For further information on hypersensit ivity reactions, 
please refer to Section  8.9.2  and Appendix 3 (Section 
10.3.3 ). 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  19 of 100 
 
Potential risks:  
Antibody formation leading 
to changes in clinical effect  Antibodies to exogenously 
delivered insulin are common with insulin 
treatment but are not often 
clinically significant.  
In NN1436- 4383 clinical 
trial, the proportion of subjects with anti- insulin 
antibodies was higher with insulin icodec (82.1%) 
than insulin glargine 
(35.0%).  
Maximum level of antibody response was higher against insulin icodec than insulin glargine.  
No apparent relationship between antibody titres and change in HbA
1c or 
weekly insulin dose was observed.   Blood samples will be taken for analysis of serum 
antibodies against insulin icodec at pre -first dose time 
point. Then at appropriate time points during the trial 
and at the end of trial visit. Confirmed anti- insulin 
icodec antibody positive samples will h ave an antibody 
titer value determined and will be further tested for 
cross- reactivity to endogenous insulin. There will be a 
close monitoring of the glycemic control on subject level during the trial. In case lack of clinical effect is 
observed, rescue medication will be provided if 
deemed necessary.
 
In the case of systemic hypersensitivity reaction blood sampling for assessment of antibodies against insulin icodec, as well as other assessments will be conducted. 
For more information, please refer to Section 8.9.2
 and 
Appendix 3 (Section 10.3.3 ). 
Trial procedures  
Potential risk:  
COVID- [ADDRESS_124017] been 
taken:
 
• Cautious subject  recruitment planning ensures 
controlled subject  enrolment in countries where 
the COVID- 19 pandemic is evaluated to be 
sufficiently under control, and at sites where 
health care resources are evaluated to be adequate.  
• On-site visits will be well- prepared  and as short as 
possible. Physical contact [CONTACT_111401] s and 
site staff will be limited to the extent possible, and protective measures will be implemented ( e.g. use 
of masks, sanitizers, no aerosol -generating 
procedures etc. according to the local practice) . 
• 
A COVID- 19 mitigation plan has been developed 
for this trial which lists the additional actions to consider in case a site or country are locked down 
and subjects cannot attend on -site visits.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124018] s 
participating in this 26 -week trial, the anticipated benefits include improved glycaemic control. The 
titration algorithm in  Appendix 8 (Section  10.8 ), which specifies recommended adjustments of 
basal insulin dose  at different plasma glucose levels, will be used to ensure that subjects receive 
optimal treatment. Subjects will receive intens e medical care by [CONTACT_111402].  
2.3.3 Overall benefit -risk conclusion  
Insulin icodec is efficacious at clinically relevant doses. Titration guidance for phase 3a trials aims 
to achieve good glycaemic control without increasing the risk of hypoglycaemic events.  
No new significant safety information that changes the current benefit–risk profile of insulin icodec 
emerged from the ongoing and completed clinical trials. The safety profile of insulin icodec remains 
in line with the cumulative  experience.  
As an overall assessment, Novo Nordisk evaluates that the benefit–risk balance of insulin icodec remains favourable.  
Considering the measures taken to minimise risk to subjects participating in this trial, the potential risks identified in association with insulin icodec are justified by [CONTACT_111403] . 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  21 of 100 
 
More detailed information about the known and expected benefits and risk of insulin icodec can be 
found in the investigator’s brochure11 and any updates hereof.  
[ADDRESS_124019] on glycaemic control of once weekly insulin icodec, with or without non-insulin anti-diabetic drugs, in subjects with T2D treated with basal insulin. This includes comparing 
the difference in change from baseline in HbA
1c between insulin icodec and insulin degludec after 
26 weeks of treatment to a non- inferiority limit of 0.3%.  
3.1.2 Secondary objective  
To compare safety and patient reported outcomes with once weekly insulin icodec versus once daily 
insulin degludec, both with or without non- insulin anti -diabetic drugs, in subjects with T2D treated 
with basal insulin.  
3.1.3 Estimand 
The estimand is the ‘treatment policy estimand’ defined as the treatment difference betw een insulin 
icodec and insulin degludec of the change in HbA 1c from baseline to week 26 for all randomised 
subjects, irrespective of adherence to randomised treatment and changes to anti-diabetic background medication. The following intercurrent events will be handled by [CONTACT_17983]: 
initiation of bolus insulin treatment fo r more than 2 weeks, discontinuation of randomised insulin 
treatment, and withdrawal from the trial (measurements collected after these intercurrent events are used in the primary analysis). 
3.2 Primary, secondary and exploratory endpoints 
3.2.1 Primary endpoint  
Endpoint title  Time frame  Unit  
Change in HbA 1c From baseline week 0 (V2) to week 26 (V28)  %-point  
3.2.2 Secondary endpoints  
[IP_ADDRESS] Confirmatory secondary endpoints 
Not applicable for this trial.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  22 of 100 
 
[IP_ADDRESS] Supportive secondary endpoints  
Secondary efficacy endpoints  
Endpoint title  Time frame  Unit  
Change in fasting plasma glucose 
(FPG)  From baseline week 0 (V2) to week 26 (V28)  mmol/L  
Time in target -range 3.9 –10.0 
mmol/L (70 -180 mg/dL)*  From week 22 (V24) to week 26 (V28)  % of readings  
Change in DTSQs (Diabetes 
Treatment Satisfaction 
Questionnaire) in total treatment satisfaction  From baseline week 0 (V2) to week 26 (V28)  Score 0 -36 
6 items scored on a 
scale of 0 to 6. The 
higher the score the greater the satisfaction 
with treatment  
* using continuous  glucose monitoring (CGM) system, Dexcom G6  
Secondary safety endpoints   
Endpoint title  Time frame  Unit  
Number of severe hypoglycaemic 
epi[INVESTIGATOR_1841] (level 3)  From  baseline  week 0 (V2) to week 31 (V30)  Number of epi[INVESTIGATOR_111345] (level 2) 
(<3.0 mmol/L (54 mg/dL), confirmed 
by [CONTACT_41132])   From baseline  week 0 (V2) to week 31 (V30)  Number of epi[INVESTIGATOR_111345] (level 2) (<3.0 mmol/ L (54 mg/dL), confirmed 
by [CONTACT_41132]) or severe 
hypoglycaemic epi[INVESTIGATOR_1841] (level 3)  From baseline  week 0 (V2) to week 31 (V30)  Number of epi[INVESTIGATOR_111346] < 3.0 mmol/L 
(54 mg/dL)*  From week 22 (V24) to week 26 (V28)  % of readings  
Time spent > 10 mmol/L 
(180 mg/dL)*  From week 22 (V24) to week 26  (V28)  % of readings  
Mean weekly insulin dose  From week 24 (V26) to week 26 (V28)  U 
Change in body weight  From baseline  week 0 (V2) to week 26 (V28)  kg  
* using continuous glucose monitoring (CGM) system,  Dexcom G6  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  23 of 100 
 
3.2.3 Exploratory endpoints 
Endpoint title  Time frame  Unit 
Number of severe hypoglycaemic  
epi[INVESTIGATOR_1841] (level 3)  From baseline week 0 (V2) to week 26 (V28)  Number of epi[INVESTIGATOR_111345] (level 2) 
(<3.0 mmol/L (54 mg/dL), confirmed 
by [CONTACT_41132])  From baseline week 0 (V2) to week 26 (V28)  Number of epi[INVESTIGATOR_111345] (level 2) (<3.0 mmol/L (54 mg/dL), confirmed 
by [CONTACT_41132]) or severe 
hypoglycaemic epi[INVESTIGATOR_1841] (level 3)  From baseline week 0 (V2) to week 26 (V28)  Number of epi[INVESTIGATOR_1841]  
[ADDRESS_124020] on 
glycaemic control , safety  and electronic patient reported outcomes (PRO s) of treatment with once 
weekly insulin icodec compared to once daily insulin degludec, both with or without non-insulin 
anti-diabetic drugs, in basal insulin treated subjects with inadequately controlled T2D on once or 
twice daily insulin.  
The trial duration is approximately 33 weeks, consisting of a 2-week screening period, followed by 
a 26-week randomised treatment period and a 5-week follow-up period. The overall trial design and 
visit schedule are outlined in Figure 4-1 and trial flowchart (Section  1.2), respectively. 
 
Figure 4-1 Trial design  
Subjects will be randomised (1:1) to receive once weekly insulin icodec or once daily insulin degludec. The dose and dosing frequency of any pre- trial non -insulin anti- diabetic treatment should 
not be changed during the trial unless due to safety concerns; except for treatment with sulfonylureas and glinides that must be discontinued at randomisation. During the 26- week 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124021] with the site weekly either at site visits or by [CONTACT_648]. 
The end of treatment visit (V 28) will be one week after the last dose of insulin icodec and on the 
day of or the day after the last dose of insulin degludec. Two follow-up visits (V29 and V30) will be 
performed [ADDRESS_124022] continuous glucose monitoring 
(CGM ) profiles collected, as specified in the flowchart (Section 1.2). The CGM data will be blinded 
for both subjects and investigators. 
Event adjudication will be performed for acute coronary syndrome events (acute myocardial 
infarction or unstable angina pectoris requiring hospi[INVESTIGATOR_11956]), cerebrovascular events (stroke or 
transient ischemic attack), heart failure (requiring hospi[INVESTIGATOR_111347]) and 
all-cause death.  
4.[ADDRESS_124023] on glycaemic control , safety and PROs of once weekly 
insulin icodec versus once daily insulin degludec during 26 weeks of treatment. 
Currently, basal insulins are dosed once or twice daily. In order to compare to well established and 
widely used basal insulin analogues with once daily dosing, insulin degludec has been chosen as 
comparator.  
The treatment arms will be open label as it was not considered feasible to blind the two treatments 
due to assessment of treatment satisfaction and preference. Patient reported outcome questionnaires 
are used in the trial to investigate the subjects’ exper ience of the impact on treatment burden. The 
treatment burden is expected to be reflected in treatment satisfaction and patient preference.  
The treatment duration of [ADDRESS_124024] on 
glycaemic control and safety. This duration will also allow for up- titrating the basal insulin. The 
treat-to-target approach has been chosen in order to ensure optimal titration of insulin based on self-
measured plasma glucose (SMPG) values with the aim of improving HbA 1c in the period. 
Titration of insulin icodec and insulin degludec will be based on pre-breakfast SMPG values and follow the principles outlined in the titration guideline, see Appendix 8 (Section 10.8
). CGM values 
will be used during the reporting phase to generate profiles for evaluating the effect on glycaemic control during initiation of trial product, steady state and follow-up. To avoid influence on titration 
and the glycaemic control, the CGM data will be blinded for both study subjects and investigator . 
Subjects included in the trial will already be on basal insulin analogue treatment with or without non-insulin anti-diabetic drugs ensuring a trial population representative of a broad T2D population. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124025] five half -lives of insulin icodec. 
A sufficient assay -sensitivity for the non-inferiority evaluation will be ensured by [CONTACT_111243]- to-target 
trial design, the applied titration target/algorithm together with close titration surveillance and by 
[CONTACT_111404].  
4.2.[ADDRESS_124026] input into design 
Not applicable for this trial.  
4.3 Justification for dose 
Insulin degludec will be switched from the pre -trial basal insulin analogues according to local label 
and insulin icodec will be initiated ac cording to the principles outlined in the titration guideline in 
Appendix 8 (Section 10.8 ). A 50% loading dose will be applied to avoid glycaemic slip during the 
first few weeks of treatment. No safety concerns have been identified in subjects with T2D, 
including vulnerable subjects, using a loading dose when initiating insulin icodec (trial NN1436-
4466).  
One unit of insulin icodec has similar glucose lowering effect to one unit of insulin degludec, and therefore once weekly dosing corresponds to seven times the daily dose of the once daily 
comparator.  
The PK /PD properties of insulin icodec following five weeks of once weekly dosing in subjects 
with T2D (trial NN1436-4314) showed that insulin icodec exposure was well distributed across the 
dosing interval, with a PK profile suitable for once weekly dosing. Insulin icodec was well tolerated 
in subjects with T2D and no unexpected  safety concerns were identified after multiple once weekly 
dosing in the dose range of 12−24 nmol/kg (2-4 units/kg).  
After randomisation, subjects should start once daily insulin degludec or once weekly insulin icodec 
injections on the same day. Due to the longer half-life of insulin icodec, the last dose of insulin 
icodec will be administered [ADDRESS_124027] dose of once daily insulin 
degludec will be administered  26 weeks after randomisation. The follow-up period for both insulin 
icodec and insulin degludec will b e the 5 weeks from end of treatment (V 28) until end of trial 
(V30). 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  26 of 100 
 
Further details on dose adjustment can be found in the titration guideline in 
Appendix 8 (Section  10.8 ). 
4.[ADDRESS_124028] completed the trial if he/she has completed all phases of the trial 
including the last visit.  
The end of the trial is defined as the date of the last visit of the last subject in the trial globally . 
5 Trial population 
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1 Inclusion criteria  
Subjects  are eligible to be included in the trial only if all the following criteria apply:  
1. Informed consent obtained before any trial- related activities. Trial- related activities are any  
procedures that are carried out as part of the trial, including activities to determine suitability 
for the trial.  
2. Male or female.  
3. Age above or equal to 18 years at the time of signing informed consent. 
4. Diagnosed with T2D ≥ 180 days prior to the day of screening. 
5. HbA 1c from 7.0-10.0% (53.0-85.8 mmol/mol) both inclusive at screening confirmed by 
[CONTACT_111405].  
6. Treated with once daily or twice daily basal  insulin (Neutral Protamine Hagedorn insulin, 
insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) ≥ 90 days prior to the day of screening with or without any of the following anti-
diabetic drugs/regimens with stable doses ≥ 90 days prior to screening: 
• Metformin  
• Sulfonylureas 
• Meglitinides (glinides)  
• DPP-4 inhibitors 
• SGLT2 inhibitors 
• Thiazolidinediones 
• Alpha-glucosidase inhibitors 
• Oral combination products (for the allowed individual oral anti-diabetic 
drugs) 
• Oral or injectable GLP -1 RAs 
7. Body mass index (BMI) ≤ 40.0 kg/m
2. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  27 of 100 
 
5.2 Exclusion criteria  
Subjects are excluded from the trial if any of the following criteria apply: 
1. Known or suspected hypersensitivity to trial product(s) or related products. 
2. Previous participation in this trial. Participation is defined as signed informed consent. 
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measures 
as required by [CONTACT_17993]). 
4. Participation in any clinical trial of an approved or non-approved investigational medicinal product within 90 days before screening
a. 
5. Any disorder, except for conditions associated with T2D , which in the investigator’s opi[INVESTIGATOR_111348]’s safety or compliance with the protocol. 
6. Any epi[INVESTIGATOR_111349] 90 days prior to the day of screening. 
7. Myocardial infarction, stroke, hospi[INVESTIGATOR_111350] 180 days prior to the day of screening. 
8. Chronic heart failure classified as being in [LOCATION_001] Heart Association Class IV at screening. 
9. Planned coronary, carotid or peripheral artery revascularisation. 
10. Renal impairment with estimated glomerular filtration rate value of < 30 ml/min/1.73m
2 at 
screening16 by [CONTACT_111405].  
11. Impaired liver function, defined as Alanine Aminotransferase ≥ 2.5 times or Bilirubin >1.5 
times upper normal limit at screening by [CONTACT_111405].  
12. Known hypoglycaemic  unawareness as indicated by [CONTACT_111397]’s 
questionnaire question 817 (Section 8.2). 
13. Recurrent severe hypoglycaemic  epi[INVESTIGATOR_111351]. 
14. Inadequately treated blood pressure defined as systolic ≥180 mmHg or diastolic 
≥110 mmHg at screening.  
15. Treatment with any medication for the indication of diabetes or obesity other than stated in 
the inclusion criteria within 90 days prior to the day of screening. 
16. Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid 
hormones, or corticosteroids). 
17. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  28 of 100 
 
between screening and randomisation. Pharmacological pupil- dilation is a requirement 
unless using a digital fundus photography camera specified for non- dilated examination.  
18. Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, 
in-situ carcinomas of the cervix, or in situ prostate cancer) within [ADDRESS_124029] or in the medical records.  
5.3 Lifestyle considerations  
5.3.1 Meals and dietary restrictions  
The subjects should be fasting when attending some of the visits, see flowchart (Section 1.2 ). 
Fasting is defined as at least [ADDRESS_124030] one cigarette or equivalent daily. 
5.3.3 Physical activity 
Not applicable for this trial. 
5.4 Screen failures  
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
eligible for participation according to inclusion/exclusion criteria. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure subjects to meet 
requirements from regulatory authorities. Minimal information includes informed consent date, 
demography, screen failure details, and eligibility criteria.  
A screen failure session must be made in the interactive web response system (IWRS).  
Individuals who do not meet the criteria for participation in this trial may not be rescreened. If the 
subject has failed one of the inclusion criteria or fulfilled one of the exclusion criteria related to 
laboratory parameters, re-sampling is not allowed. However, in case of technical issues (e.g. 
haemolysed or lost), re- sampling is allowed for the affected parameters.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  29 of 100 
 
5.5 Run-in criteria, randomisation criteria and dosing day crit eria 
Not applicable for this trial.  
6 Treatments 
6.1 Treatments administered  
Investigational medicinal products (IMP) 
All investigational medical products (IMPs) are listed in Table 6-[ADDRESS_124031] name:  [CONTACT_111445] 700 units/mL  
(IMP, test product)  Insulin degludec 100 units/mL  
(IMP, reference therapy)  
Dosage form  Solution for injection  Solution for injection  
Route of administration  Subcutaneous (into the thigh, upper 
arm or abdomen)  Subcutaneous (into the thigh, upper arm 
or abdomen)   
Recommended initial dose  Please refer to Appendix 8 , Section 
10.8 Please refer to Appendix 8, Section 10.8 
Dosing instructions  Administer insulin icodec once weekly, 
on the same day each week, at any time 
of the day.  The day of weekly 
administration can be changed if necessary, by [CONTACT_8622] 3 days. A minimum of 4 days between injections should always be ensured.  
Rotation of injection site is 
recommended . Administer insulin degludec once daily 
at any time of the day, but at the same time eve ry day throughout the trial. 
Rotation of injection site is recommended.  
Packaging  3 mL PDS290 pre -filled pen -injector  3 mL PDS290 pre-filled pen-injector  
• At randomisation visit (V2) subjects should administer trial drug at site  
• Subjects should be instructed to discard the needle after each injection and store the 
pen-injector without a needle attached.  
Non-investigational medicinal products (NIMP) 
After randomisation subjects should continue their pre-trial non-insulin anti-diabetic background 
medication throughout the entire trial except from sulfonylureas and glinides, which must be 
discontinued at randomisation. The background medication should be maintained at the stable, pre-
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  30 of 100 
 
trial dose and at the same frequency during the entire treatment period unless due to safety 
concerns.  
In addition, the background medication: 
• is considered to be non-investigational medicinal product (NIMP) 
• will not be provided by [CONTACT_111406]  
• should be used in accordance with standard of care or local label in the individual country at the discretion of the investigator.  
Auxil iary supplies  
Auxiliary supplies comprise supplies other than trial products. Auxiliary supplies will be provided in accordance with the trial materials manual, please see Table 6-[ADDRESS_124032].  
Blood glucose  (BG)  
meter  At randomisation (V2) subjects must be instructed in how to use the BG meter and the 
BG meter should be linked to the eDiary as described in the eDiary site guide.  
Please refer to the [COMPANY_002] manufacturer’s guide .  
Continuous glucose 
monitoring  (CGM) 
system  At randomisation (V2) subjects must be instructed in handling of the CGM.  
Please refer to the Dexcom G6® manufacturer’s guide provided.  
eDiary  Subject Mobile App, HCP Web Portal, & Cloud Service . 
Please refer to the eDiary site guide.  
• Information about the PDS290 pre- filled pen -injector can be found in the directions for use 
provided in the eDiary. 
• Training in the pen-injectors is the responsibility of the investigator or a delegate and must be 
repeated during the trial at regular intervals, as specified in the flowchart (see Section 1.2) in 
order to ensure correct use of the pen -injector.  
6.1.1 Medical devices  
[IP_ADDRESS] Investigational medical device  
Not applicable for this trial. 
[IP_ADDRESS] Non-investigational medical devices 
Non-investigational medical devices are listed  as auxiliary supplie s (Table 6-2 ). 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  31 of 100 
 
For the countries where BG meter and CGM are not approved, please refer to the Appendix 9 
(Section 10.9) country- specific requirements for further information . 
6.2 Preparation/handling/storage/accountability  
Only subjects randomised to treatment may use trial product and only delegated site staff may 
supply trial product. 
• Acceptable temperature ranges and conditions for storage and handling of each trial product 
when not in use and when in use ar e described in the trial material manual and trial product 
label.  
• Each site will be supplied with sufficient trial product for the trial on an ongoing basis. Trial 
product will be distributed to the sites according to screening and randomisation. 
• The investigator or designee must confirm that appropriate temperature conditions have been 
maintained during transit for all trial products received, and that any discrepancies are reported 
and resolved before use of the trial products. 
• All trial products must be stored in a secure, controlled, and monitored (manual or automated) 
area in accordance with the labelled storage conditions with access limited to the investigator 
and delegated site staff.  
• The investigator must inform Novo Nordisk immediately if any trial product has been stored 
outside specified conditions. The trial product must not be dispensed to any subject before it has been evaluated and approved for further use by [CONTACT_3454]. Additional details 
regarding handling of temperature deviations can be found in the t rial material manual . 
• The investigator or designee is responsible for drug accountability and record maintenance (i.e. 
receipt, accountability and final disposition records). 
• The investigator or designee must instruct the subject in what to return at next visit . 
• Each single pen should be accounted. 
• Destruction of trial products can be performed on an ongoing basis and will be done according 
to local procedures after accountability is finalised by [CONTACT_41138]. 
• All returned, un-used, expi[INVESTIGATOR_17945] (for technical complaint samples, see 
Section 10.5
) must be stored separately from non- allocated trial products. No temperature 
monitoring is required. 
• Non-allocated trial products including expi[INVESTIGATOR_41073], at the latest at closure of the site.  
6.3 Measures to minimise bias: Randomisation and blinding 
• This is an open label trial; however, the specific treatment for a subject will be assigned using 
an IWRS. The site will access the IWRS before the start of t rial product administration for 
each subject. Potential bias will be reduced by [CONTACT_111407]. 
• All subjects will be centrally screened and randomised using an IWRS and assigned to the next 
available treatment according to randomisation schedule. Trial product will be dispensed/allocated at the trial visits summarised in the flowchart (Section 1.2).
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124033] administration 
will be assessed by [CONTACT_111408]: 
• Drug accountability information 
• Review of eDiaries including SMPG profiles, insulin dose and hypoglycaemia reporting 
• Evaluating glycaemic contr ol and adherence to the visit schedule 
• If any suspi[INVESTIGATOR_17946]- compliance arises the site must enter into a dialogue with the subject , 
re-emphasizing the importance of compliance and uncover barriers to compliance. This 
dialogue must be documented in the m edical record.  
6.[ADDRESS_124034] receives  
from screening (V1) until end of trial visit ( V30) must be recorded along with: 
• Generic name [CONTACT_111446]  
• Indication  
• Dates of administration including start and stop date. 
Concomitant medication (diabetes)  
Any anti-diabetic medication other than the trial product that the subject receives from screening 
(V1) until end of trial visi t (V30) must be recorded in a separate concomitant medication (diabetes) 
form in the electronic case report form  (eCRF ).  
The following information must be recorded for oral anti-diabetic drugs, GLP-[ADDRESS_124035]- treatment insulin in the follow -up period: 
• Generic name [CONTACT_111446] (for insulin products: only trade name). 
• Dates of administration including start and stop date. 
• Doses and  frequency (e.g. once daily, twice daily). 
Until end of treatment (V 28) only randomised treatment (trial products and pre- trial non -insulin 
anti-diabetic background medication except for sulfonylureas and glinides which must be 
discontinued at randomisation) are allowed, unless due to safety reasons at the discretion of the investigator. If the investigator chooses to initiate anti-diabetic medication or change dose of pre-
trial anti-diabetic background medication prior to end of treatment (V28), this shoul d be registered 
in the eCRF as change in concomitant medication (diabetes).  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124036] see Section 7 . 
6.5.1 Rescue medication or Rescue therapy  
Not applicable for this trial. 
6.6 Dose modification 
Doses are adjusted according to blood/plasma glucose values as described in 
Appendix 8 (Section  10.8 ). 
6.6.[ADDRESS_124037]- trial treatment includes a new insulin 
treatment, please refer to the titration guideline in Appendix 8 (Section 10.8 ).  
[ADDRESS_124038] 
discontinuation/withdrawal 
Treatment of a subject may be discontinued at any time during the trial at the discretion of the 
investigator for s afety, behavioural, compliance or administrative reasons. 
Efforts must be made to have the subjects who discontinue trial product attend the end of treatment visit (V 28) as soon as possible to collect the required data for the analysis of the primary endpoint. 
Two follow-up visits, V29  and V30 , must be performed after discontinuation of the trial product. 
Visits V29 and V30  must be conducted [ADDRESS_124039] should keep and use the eDiary, and return it at the follow-up visit 2 (V30).  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124040] status in the HCP web portal to 'Follow-up' at the end of 
treatment visit to ensure that the subject should no longer report insulin dose. 
Continue to collect, record and report AEs as described in Section 8.3 . AEs  and anti -diabetic 
medication should be collected and recorded in the eCRF until the discontinuation follow-up visit 
(V28A) for discontinued subjects, no other concomitant medication will be collected. Please, refer 
to Section  6.[ADDRESS_124041] with discontinued subjects by [CONTACT_17084]/or site 
visits to motivate subjects to attend the visits until the discontinuation follow-up visit (V28A). Site 
contact [CONTACT_111409]. 
7.[ADDRESS_124042]: 
1. Safety concern related to trial product or unacceptable intolerability 
2. Pregnancy  
3. Intention of becoming pregnant 
4. Simultaneous use of an approved or non-approved investigational medicinal product in another clinical trial
a 
5. Lack of efficacy,  defined as fulfilment of ALL  4 criteria below:  
a. No reduction in HbA 1c measured by [CONTACT_41140] (V2) to 
V12, or to V20, AND  
b. The pre-breakfast SMPG readings on 3 consecutive days higher than 240 mg/dL 
(13.3 mmol/L) within the last tw o weeks period despi[INVESTIGATOR_111352]  
c. A confirmatory fasting plasma glucose exceeding 240 mg/dL (13.3 mmol/L) 
measured by [CONTACT_12115]. The subject should come in for an unscheduled visit 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  35 of 100 
 
as soon as possible (within one week), the next scheduled visit should not be awaited 
AND  
d. No treatable intercurrent cause (e.g. non- compliance) for the hyperglycaemia at the 
investigator’s judgment. 
a Simultaneous participation in a trial with the primary objective of evaluating an approved or non-approved 
investigational medicinal product for prevention or treatment of COVID -[ADDRESS_124043], who does not fulfil the eligibility (inclusion/exclusion) criteria, must not be randomised. Randomisation in violation of any of the eligibility criteria is good c linical practice (GCP) non -
compliance and must be reported to the sponsor without delay. This will be handled as an important protocol deviation, and the independent ethics committee/institutional review board (IEC/IRB) and 
regulatory authorities must be notified according to local requirements.  
Subjects that are randomised in violation of inclusion and exclusion criteria can be allowed to 
continue in the trial and receive t rial product if there are no safety concerns as evaluated by [CONTACT_111410]. 
7.1.[ADDRESS_124044] discontinuation/withdrawal from the trial  
A subject may withdraw consent at any time at his/her own request. If a subject withdraws consent, 
the investigator must ask the subject if he/she is willing, as soon as possible, to have assessment 
performed according to the end of treatment visit (V28). See the flowchart (Section  1.2) for data to 
be collected.  
Final drug accountability must be performed even if the subject is not able to come to the site . A 
treatment status session must be made in the IWRS. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124045] withdraws from the trial, he/she may request destruction of any samples taken and not 
tested, and the investigator must document this in the medical record.  
Although a subject is not obliged to give his/her reason(s) for withdrawing, the investigator must make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where 
the reasons are obtained, the primary reason for withdrawal must be specified in the end of trial 
form  in the eCRF.  
7.2.[ADDRESS_124046] to follow-up if he/she repeatedly fails to return for scheduled visits 
and is unable to be contact[CONTACT_55654]. 
The following actions must be taken if a subject fails to return to the site for a required visit: 
• The site must attempt to co ntact the subject and reschedule the missed visit as soon as possible 
and counsel the subject on the importance of maintaining the assigned visit schedule and 
ascertain whether or not the subject wishes to and/or should continue in the trial. 
• Before a subject is deemed lost to follow-up, the investigator or designee must make every 
effort to regain contact [CONTACT_1155] (where possible, at least three telephone calls and, if necessary, a certified letter to the subject's last known mailing address or local equivalent 
methods). These contact [CONTACT_9300]'s source document. 
• Should the subject continue to be unreachable, he/she will be considered to have withdrawn 
from the trial with a primary reason of `lost to follow -up'. 
8 Trial assessments and procedures  
The following sections describe the assessments and procedures, while their timing is summarised 
in the flowchart (Section 1.2 ). 
• Informed consent must be obtained before any trial related activity, see 
Appendix 1 (Section  10.1.3 ). 
• All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all inclusion criteria and none of the exclusion criteria.  
• The investigator will maintain a sc reening log to record details of all subjects screened and to 
confirm eligibility or record reason for screen failure, as applicable. 
• At screening, subjects will be provided with a card stating that they are participating in a trial 
and giving contact [CONTACT_111411].   
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  37 of 100 
 
• Adherence to the trial design requirements, including those specified in the flowchart, is 
essential and required for trial conduct.  
• Assessments should be carried out according to the clinic’s standard of practice unless specified 
in the current section. Efforts should be made to limit the bias between the assessments. The 
suggested order of the assessments at randomisation visit (V2) is as follows: 
o Blood sample collection  
o Other assessments to confirm eligibility  
o Randomisation in IWRS 
o Continuous glucose monitoring fitting and training  
o The investigator should create a subject profile and record administrative 
information (e.g. subject ID, year of birth and gender and treatment arm in the HCP 
web portal  
o Subjects should be provided with an eDiary and instructed in how to use it.  
o The BG meter should be connected with the eDiary  
o A fasting SMPG should be measured using the BG meter 
o Dosing of trial product  
• For information regarding the eDiary and HCP web portal please refer to the site guide.  
• Please refer to Section 6.4 for drug treatment compliance. 
• All data entered in the eDiary is considered source data. The investigator should review all the 
data for the subjects through the HCP web portal, before or during each visit/phone contact. 
• Review of eDiary, ECG, laboratory reports, eye- and physical examinations must be 
documented either on the documents or in the subject's source documents. If clarification of entries or discrepancies in the eDiary is needed, the subject must be questioned, and a 
conclusion made in the subject's source documents, the eDiary should be updated 
retrospectively if applicable. Care must be taken not to bias the subject. 
• Source data of clinical assessments performed and recorded in the eCRF must be available and 
will usually be in the subject’s medical records. Additional recording to be considered source 
data includes, but is not limited to; laboratory reports, BG meter, CGM, pi[INVESTIGATOR_111353].  
• The investigator should ensure that the electronic patient reported outcome questionnaires are 
completed by [CONTACT_111412]. 
• Repeat samples may be taken for technical issues and unscheduled samples or assessments may 
be taken for safety reasons. Please refer to Appendix 2 (Section 10.2
) for further details on 
laboratory samples . 
8.1 Efficacy assessments  
Planned time points for all efficacy assessments are provided in the flowchart (Section 1.2 ). 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  38 of 100 
 
8.1.1 Self-measured plasma glucose (SMPG)  
Subjects will be provided with a blood glucose meter including auxiliaries. The BG meters use test 
strips calibrated to plasma values. Therefore, all measurements performed with capi[INVESTIGATOR_111354], which will be shown on the display.  
The BG meter provided by [CONTACT_111413], as described in the flowchart (Section 1.2 ). 
A baseline SMPG value, in fasting condition, should be collected using the BG meter at V2.  
Pre-breakfast daily SMPG  
Subjects should be instructed to measure their pre-breakfast SMPG daily from week 0 (V2) to end 
of trial (V30) and to transfer the measured SMPG values into the eDiary.  
Selected titration data (e.g. certain SMPGs and dose data) from the eDiary will be used during the 
trial for central titration surveillance, to ensure compliance with the titration guideline in 
Appendix 8 (Section  10.8 ) and will not be reported in the clinical trial report. All data will be stored 
by [CONTACT_3454] (see Appendix 1, Section 10.1). 
8.1.2 Continuous glucose monitoring  
Subjects will be equipped with a CGM device during the treatment periods from week 0 (V2) to 
week 4  (V6), and from week 22 (V24) to week 26 (V28) and during the follow-up period from 
week 26  (V28) to week 31 (V30).  
The CGM system used in this trial will be the Dexcom G6®. 
The CGM readings will be blinded to both the subject and investigator and will not be used for any insulin dose titration or hypoglycaemic epi[INVESTIGATOR_41076]. 
If a subject withdraws consent during the trial, a site visit should be scheduled in order to remove 
the CGM sensor and upload the data from the receiver. 
CGM fitting and training  
The site staff will closely supervise and assist on fitting of the sensor and transmitter on the subject 
during the site vi sits. Training in the CGM is the responsibility of the investigator or site staff at the 
relevant visits. For information on fitting, and changing of the CGM parts, please refer to the manufacturer’s manual and subject guide provided. 
CGM Sensor Check  
The site staff should ensure that the subject has fitted the sensor correctly and that the CGM 
receiver is working. This will be done in person during the clinic visit, as specified in the flowchart 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  39 of 100 
 
(Section  1.2). At the end of treatment visit (V28), the site should ensure the subject can change the 
sensor at home weekly during the follow-up period.  
CGM Upload  
Data stored on the CGM receiver must be uploaded at the site by [CONTACT_111414]. The upload will be documented by [CONTACT_111415].  
The serial number of the CGM receiver must be recorded in the eCRF at the start of each CGM period. In case the CGM receiver is being replaced, the serial number should be updated. 
8.1.[ADDRESS_124047] without assistance 
of the site personnel and should preferably be completed after all fasting -related activities are 
completed, but before any other visit related procedures are conducted. It takes approximately five 
minutes to complete the questionnaires. 
The following patient reported outcome questionnaires will be supplied in the eDiary in a 
linguistically validated version in all languages relevant for this trial: 
• Diabetes Treatment Satisfaction Questionnaire (DTSQ s)  
o The questionnaire has been designed to measure satisfaction with diabetes treatment regimens in people with diabetes. The DTSQs questionnaire will be measured at 
baseline (V2) and end of  treatment  (V28).  
• Insulin preference questionnaire version 1.0 (IPQ)  
o The instrument assesses the preferences for specific insulin treatment in the trial 
setting and asks about the preference of a once weekly insulin (taken in the trial) 
compared with daily insulin (that was taken before the trial). The questionnaire will 
be measured at end  of treatment (V28) in subjects treated with once weekly insulin 
icodec.  
• Diabetes Pen Experience Measure version 3.0 (DPEM)  
o The questionnaire is designed to measure subjects' experience of insulin injection pen in terms of easiness, convenience and satisfaction. The DPEM questionnaire will 
be measured at baseline (V2) and end of  treatment (V28). 
8.1.4 Clinical efficacy laboratory assessments 
All protocol-required laboratory assessments, as defined in Appendix 2 (Section 10.2
), must be 
conducted in accordance with the flowchart (Section 1.2) and the laboratory manual . 
8.2 Safety assessments  
Planned time points for all safety assessments are provided in the flowchart (Section 1.2). 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124048] the fin ding on the Medical 
History/Concomitant Illness form.  
With regard to exclusion criteria 12 (Section 5.2 ), information on hypoglycaemia unawareness wil l 
be recorded according to Clarke's questionnaire, question 817. The investigator must ask the subject 
in the following way: "To what extent can you tell by [CONTACT_111416]?" Subjects answering 'never, rarely or sometimes' are considered to have impaired awareness of 
hypoglycaemia, whereas those answering “often or always” are not. 
8.2.1 Insulin dose  
The prescribed  insulin doses will be determined  by [CONTACT_111417]  (Appendix 8, Section 10.8 ). 
During the trial, starting at randomisation (V2), subjects must be instructed to report date, dose and 
time of once weekly insulin or once daily insulin  in the eDiary.  In the follow-up period if the 
subject switches to a new basal insulin, the subject should also report date, dose and time of the new basal  insulin in the eDiary. 
Please refer to Appendix 8 (Section 10.8
) for more information. 
The investigator must record the following in the eCRF 
• First and last date on trial product 
• First and last dose of trial product 
For dosing of anti- diabetic medication p rescribed in the follow-up period please see S ection 6.5 
8.2.2 Physical examinations 
A physical examination will include assessments of: 
• Head, ears, eyes, nose, throat, neck  
• Cardiovascular system  
• Respi[INVESTIGATOR_2133]  
• Gastrointestinal system 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  41 of 100 
 
• Central and Peripheral Nervous System 
• Musculoskeletal system  
• Skin. 
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
The physical examination will be recorded in the eCRF as either ‘normal’ or ‘abnormal’. If 
‘abnormal’, a comment must be given together with an assessment of clinical significance (yes/no).  
Abnormal, clinically significant findings at scr eening should be recorded as concomitant illness in 
the eCRF. At the following visits, any new abnormal, clinically significant findings or clinically 
significant deteriorations from baseline should be reported as an adverse event  
(Appendix 3, Section  10.3 ). 
Body measurements (height and weight) will also be measured and recorded. Height will be 
measured and recorded at screening visit (V1). Weight will be measured and recorded throughout 
the trial as specified in the flowchart (Section 1.2). 
o Body weight should be measured in kilogram (kg) or pounds (lb) without coat and shoes wearing only light clothing. Body weight will be recorded to one decimal.  
o Body weight should be assessed with the same equipment throughout the trial, if possible. 
o Heigh t should be measured in centimetres (cm) or inches (in) without shoes. Height 
will be recorded to the nearest whole number.  
o From the body weight and height, the BMI should be calculated and recorded in the subject’s medical record s.  
8.2.3 Vital signs  
• Pulse rate, as well as systolic and diastolic blood pressure will be assessed. 
• Blood pressure and pulse rate measurements should be preceded by [CONTACT_2669] [ADDRESS_124049] in a quiet setting without distractions (e.g. no use of television, mobile  phones).  
• Blood pressure and pulse rate measurements will be assessed sitting with a completely 
automated device. Manual techniques must be used only if an automated device is not available.  
• Blood pressure and pulse rate at screening (V1), V16, and end of treat ment (V28) will consist 
of [ADDRESS_124050] two readings 
on systolic or diastolic blood pressure differ by >[ADDRESS_124051] be recorded in the eCRF.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  42 of 100 
 
• Pulse rate will be measured in connection to the blood pressure measurements. Record the pulse 
rate for the last [ADDRESS_124052]  2 measurements.  
8.2.4 Electrocardiograms  
• A [ADDRESS_124053] be performed by [CONTACT_111418] (Section 1.2 ). 
• The ECG should be preceded by [CONTACT_2669] [ADDRESS_124054] in a supi[INVESTIGATOR_050]/sitting 
position in a quiet setting without distractions (e.g. no use of television, mobile  phones).  
• The ECG must be interpreted, signed and dated by [CONTACT_41152] . 
• The ECG required at screening can be obtained within [ADDRESS_124055].  
• The ECG required at the end of treatment visit can be obtained within [ADDRESS_124056] be available for evaluation at the end of treatment visit.  
• Abnormal, clinically significant findings at screening should be recorded as concomitant illness 
in the eCRF. At the following visits, any new abnormal, clinically significant findings or 
clinically significant deteriorations from baseline should be reported as an adverse event  
(Appendix 3, Se ction 10.3 ).  
8.2.[ADDRESS_124057] or another suitably qualified hea lth 
care provider (e.g. optometrist) must be available and evaluated by [CONTACT_111419]. The eye examination should be performed as a fundus 
photography (e.g. 2-field 60 degree or better, colour or red- free) or b y slit-lamp biomicroscopy 
examination (e.g. using a pre- corneal or corneal contact [CONTACT_41158]). Pharmacological pupil -
dilation is a requirement unless using a digital fundus photography camera specified for non- dilated 
examination. 
If the subject had  such an eye examination performed within 90 days prior to screening, the 
investigator may base his/her evaluation upon the results of that examination. The examination must 
be repeated before randomisation if the subject has experienced worsening of visual function since 
the last examination. Eye examinations performed prior to randomisation visit (V2) are acceptable 
if results are available for evaluation before randomisation. If the applicable eye examination was 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124058] be documented that the 
reason for performing the examination was not related to this trial. 
Eye examinations required at the end of treatment (V28) visit can be performed within [ADDRESS_124059] be recorded as concomitant illness/medical history. While relevant findings occurring after 
randomisation should be reported as an adverse event , please refer to Section  8.3. 
8.2.6 Clinical safety laboratory assessments 
All protocol-required laboratory assessments, as defined in Appendix 2 (Section 10.2 ), must be 
conducted in accordance with the flowchart  (Section 1.2) and laboratory manual . 
8.3 Adverse events and serious adverse events  
The investigator is responsible for detecting, documenting, recording and following up on events that meet the definition of a n AE or SAE.  
The definition of AEs and SAEs can be found in Appendix 3 (Section 10.3
), along with a 
description of events for adjudication and AEs requiring additional data collection. 
Some AEs require additional data collection on a specific event form. This always includes medication, misuse and abuse of IMP. The relevant events are in Table 8-[ADDRESS_124060] be filled in in the eCRF, please refer 
to Appendix 3. For more information on hypoglycaemic epi[INVESTIGATOR_1841], please refer to 
Appendix 7 (Section 10.7
). 
Table 8-1 AEs requiring additional data collection (serious and non-serious AEs), and 
events for adjudication   
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  44 of 100 
 
Event type   AE requiring additional data 
collection  Event for adjudication  
 
Medication error  X  
Misuse and abuse  X  
Acute coronary syndrome (acute myocardial 
infarction or unstable angina pectoris requiring 
hospi[INVESTIGATOR_11956])   X 
Cerebrovascular eventsa (stroke or transient 
ischemic attack)   X 
Heart failure (requiring hospi[INVESTIGATOR_111355])   X 
Death   X 
Hypersensitivity  X  
Injection Site Reaction  X  
a All cerebrovascular events are to be reported and sent for adjudication, however the EAC will only confirm strokes.  
A detailed description of the events mentioned in the above table can be found in 
Appendix 3 (Section  10.3.3 ). 
Events for Adjudication  
Event adjudication will be performed in randomised subjects and will be evaluated by [CONTACT_111420] a blinded manner, please refer to Section [IP_ADDRESS]
. 
There are four ways to identify events relevant for adjudication as described below:  
• Investigator-reported events for adjudication: investigator selects the appropriate AE category relevant for adjudication (Appendix 3, Section 10.3.3
). 
• AEs reported with fatal outcome .  
• AE search (standardised screening): All AEs not reported with an AE category relevant for adjudication will undergo screening to identify potential events for adjudication. Investigators will be notified of these events in the eCRF.  
• EAC -identified events: Unreported events relevant for adjudication identified by [CONTACT_111421].  
Investigators will be notified of these events in the eCRF and has the option to report the 
EAC -identified event. 
For each event relevant for adjudication an event type specific adjudication form should be completed in the eCRF within 14 days. 
Copi[INVESTIGATOR_111356] (EAS) as soon as 
possible and preferably within 4 weeks. In cases where the EAS is not accessible the investigator 
should ensure that the relevant source documents are collected and saved locally until the EAS is 
ready. If no, or insufficient source documents are provided to the adjudication supplier, the 
investigator can be asked to complete a clinical narrative to be uploaded to the EAS.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124061] be collected from the randomisation visit and until the end of trial visit as  
specified in the flowchart  (Section 1.2). For subjects discontinuing trial product prematurely AEs 
must be collected until the discontinuation follow-up visit (V28A). 
Medical occurrences that take place or have onset prior to the time point from which AEs are collected will be recorded as concomitant illness/medical history. AE and SAE reporting timelines 
can be found in Appendix 3 (Section 10.3
). All SAEs must be recorded and reported to Novo 
Nordisk within [ADDRESS_124062] has been 
discontinued from/completed the trial, and the investigator considers the event to be 
possibly/probably related to the trial product or related to trial participation, the investigator must 
promptly notify Novo Nordisk. 
8.3.2 Method of detecting AEs and SAEs  
The method of recording, evaluating and assessing causality of AE and SAE and the procedures for 
completing and transmitting SAE reports are provided in Appendix 3 (Section 10.3
). 
Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-leading verbal questioning of the subject is the preferred method to inquire about events. 
8.3.3 Follow- up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactiv ely follow each subject at 
subsequent visits/contacts. All SAEs  should be followed until final outcome of the event or the 
subject is lost to follow -up as described in Section 7.3
. Further information on follow-up and final 
outcome of events is given in Appendix 3 (Section 10.3). 
8.3.[ADDRESS_124063] under clinical investigation are met.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124064] under clinical investigation. Novo Nordisk 
will comply with country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC and investigators. This also includes suspected unexpected serious adverse reactions (S[LOCATION_003]R ). 
An investigator who receives an investigator safety report describing a SAE or other specific safety information (e.g. summary or listing of SAEs) from Novo Nordisk will review and then file it along 
with the investigator's brochure and will notify the IRB/IEC, if appropriate according to local 
requirements.  
8.3.[ADDRESS_124065] becomes pregnant, the investigator should inform Novo Nordisk within 14 
calendar days of learning of the pregnancy and should follow the procedures outlined in Appendix 4 (Section 10.4
). 
8.3.6 Cardiovascular and death events  
Cardiovascular and  death events will be handled and reported according to Section 8.3 . 
8.3.7 Disease -related events and/or disease-related outcomes not qualifying as an AE or 
SAE  
Not applicable for this trial.  
8.3.[ADDRESS_124066] expedited 
reporting by [CONTACT_473]. Only adverse events fulfilling the seriousness criteria are considered for expedited 
reporting in this trial.  
8.3.9 Technical complaints  
Technical complaints will be collected for all products listed on the technical complaint form.  
Instructions for reporting technical complaints can be found in Appendix 5 (Section 10.5 ). 
In order for Novo Nordisk to perform a complete investigation of reported SAEs, Novo Nordisk 
might ask the investigator to complete a technical complaint form.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124067] be reported 
as misuse and abuse, please refer to Section 8.3 and Appendix 3 (Section 10.3.3 ) for further details.  
In the event of an overdose, the investigator should closely monitor the subject for overdose- related 
AE/SAE and laboratory abnormalities until the blood glucose is normalised and (or) 
signs/symptoms have been relieved. 
A specific overdose for insulin icodec cannot be defined; however, hypoglycaemia may develop 
over sequential stages if th e doses administered are too high relative to the subject’s requirements.  
• Mild hypoglycaemia can be treated by [CONTACT_41147].  
• Severe hypoglycaemia, where the subject is not able to treat him/herself, can be treated by [CONTACT_41148] (0.5 to 1 mg) given intramuscularly or subcutaneous ly by a trained person, or by 
[CONTACT_111422] i.v. by a medical professional. Glucose must also be given i.v., if the subject  
dose not respond to glucagon within 10-[ADDRESS_124068] . 
For more information on overdose, also consult the current version of the insulin icodec investigator’s brochure
11 or insulin degludec investigator’s brochure12. 
8.5 Pharmacokinetics  
Blood samples will be used to evaluate the pharmacokinetics (PK) of insulin icodec. PK samples 
will be collected at the visits outlined in the flowch art (Section 1.2) for subjects randomised to 
insulin icodec. The date and exact clock time for blood sampling must be recorded. 
Bioanalysis of insulin icodec samples will be performed at a special laboratory using a validated 
luminescent oxygen channelling immunoassay. The exact method will be described in a 
bioanalytical report.  
Residual PK samples may be used for exploratory meta bolite analysis. Potential metabolite analysis 
will be reported separately from the clinical trial report.  
Genetic analyses will not be performed on these plasma/serum/whole blood samples. Subject confidentiality will be maintained.  
Procedures for sampling, handling, storage, labelling and shipments of the specimens must be performed in accordance with the laboratory manual. A randomisation list will be provided to the 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  48 of 100 
 
special laboratory. Samples from randomised subjects will be analysed for insulin icode c 
concentration. 
Subjects should be instructed to report dosing information in the eDiary as per Section 8.2.1 . 
8.6 Pharmacodynamics 
Not applicable for this trial.  
8.7 Genetics  
Not applicable for this trial. 
8.8 Biomarkers  
Not applicable for this trial. 
8.9 Immunogenicity assessments  
8.9.1 Anti -drug antibodies  
Anti-drug antibody samples will be collected according to the flowchart (Section 1.2) for subjects 
randomised to insulin icodec . All samples must be drawn prior to trial product administration if trial 
product administration is planned on the sampling day. Assessment of antibodies against insulin 
icodec (anti -drug antibodies) in serum will be performed at a Novo Nordisk appointed laboratory. 
For details on blood sampling, serum preparation and storage, please refer to the laboratory manual. 
Analysis for anti -drug antibody will be done as listed in flowchart with a binding anti -drug antibody 
assay. Positive samples will be further characterised for titre, and cross -reactivity to endogenous 
human insulin. 
Detailed description of the assay methods will be included in an analytical report. Antibody assays 
will be validated according to international guidelines and recommendations. 
At the end of the trial, the following data will be electronically transferred to the Novo Nordisk 
database: Anti -insulin icodec binding antibodies (pos/neg) and titre of anti-drug antibody positive 
samples, and anti-insulin icodec binding antibodies cross-reacting with endogenous human insulin status (pos/neg). 
The investigator will not be able to review the results of antibody measurements in relation to A Es 
as the samples are often analysed after last subject last visit.  Results from the binding anti -drug 
antibody analyses from visit randomisation (V2), V4, V8, V12, V20, end of treatment (V28) and 
end of trial visit (V30) will be available  after the completion of the trial. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124069] signs and symptoms of systemic 
hypersensitivity.  
For subjects randomised to insulin icodec: In the event of a systemic hypersensitivity (not locally at 
the injection site), the subject  should be called in as soon as possible to have additional blood 
samples taken in order to analyse the following parameters: 
• Tryptase (optimal 0.5-[ADDRESS_124070] the hypersensitivity reaction)  
• Total immunoglobulin E (IgE) antibodies  
• Anti-insulin icodec IgE antibodies 
• Anti-insulin icodec binding antibodies  
• Anti-human insulin IgE antibodies  
The blood sampling should be repeated 2-[ADDRESS_124071] 
administration of trial drug.  
For details related to blood sampling, plasma preparation and storage, please refer to the laboratory manual.  
Analysis will be performed by [CONTACT_49705] a Novo Nordisk appointed special laboratory (please refer to Attachment I). The results will be reported in a separate report and attached to the 
clinical trial report. 
If the reaction is classified as a SAE, the results from the hypersensitivity tests will also be reported 
to Novo Nordisk Safety Operations for inclusion in the ARGUS database and included in the 
narratives of the clinical trial report. 
For retention of residual hypersensitivity samples, please refer to Section 10.[ADDRESS_124072] take digital pi[INVESTIGATOR_111357], using any device available (mobile phone, camera etc.) and thereaft er as often as 
judged necessary by [CONTACT_093]. The pi[INVESTIGATOR_41084], date and time, time after dosing and a ruler for scaling. All pi[INVESTIGATOR_111358].  
8.10 Health economics  
Not applicable for this trial.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  50 of 100 
 
9 Statistical considerations   
9.1 Statistical hypotheses  
The primary hypothesis to be tested is that insulin icodec is non- inferior to insulin degludec in terms 
of change from baseline to week  26 in HbA 1c. 
Formally, let D be the treatment difference ‘insulin icodec’ minus ‘insulin degludec’ of the change 
in HbA 1c from baseline to week 26. The null- hypothesis will be tested against the alternative 
hypothesis of non-inferiority as given by  
H0: D≥0.30% against HA: D <0.30% 
The n on-inferiority margin of 0.3%-point is chosen based on the recommendation in the FDA 
guidance for industry on developi[INVESTIGATOR_111359].18 Also, this margin is 
considered to provide sufficient assay sensitivity based on the below considerations: 
• The margin does not represent an unacceptable loss of efficacy with insulin icodec relative 
to treatment with a basal insulin analogue  
• It represents less than 50% of a suitably conservative estimate of insulin degludec’s 
treatment effect on HbA 1c in a placebo -controlled trial in a basal insulin treated population; 
The treatment effect of degludec versus placebo in a basal insulin treated population is 
unknown but in a similar progressed T2D population of subjects already treated with 
liraglutide, degludec was shown to be superior to placebo ( estimated treatment difference: -
0.92%-point [-1.00; -0.75] 95%CI).19 
The following describe the secondary confirmatory hypothesis. In order to control the overall Type 
I error at a 5% level, two sided, a hierarchical testing procedure will be used. If non- inferiority in 
glycaemic control is concluded in the primary analysis, confirmatory testing proceeds to the following hypothesis: 
• Insulin icodec is superior to insulin degludec in terms of change from baseline to week 26 in 
HbA
1c. 
Formally, let D be the mean treatment difference ‘insulin icodec’ minus ‘insulin degludec’ of the 
change in HbA 1c from baseline to week 26. The null-hypothesis of insulin icodec not superior will 
be tested against the alternative hypothesis of superiority as given by 
H0: D≥0 % against HA: D<0%  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124073] 90% power for declaring non- inferiority with a non-
inferiority  margin of 0.3%-point with respect to change in HbA 1c for the specified estimand and the 
full analysi s set (primary analysis set).  
Based on recent studies with basal insulins (NN9068-4185 and 4229) the percent experiencing an 
intercurrent event as specified above is expected to be 5% per 6 months in an open label study in 
subjects with T2D treated with basal insulin.  
It is assumed that there is no difference in HbA 1c between the treatment arms for subjects 
completing randomised treatment without initiation of treatment with bolus insulin for more than 2 
weeks and a treatment difference of 0.3% -point in favour of the comparator for subjects either 
discontinuing treatment prematurely, initiating treatment with bolus insulin for more than 2 weeks or withdrawing from trial. Thus, with 5% expected to experience any of the specified intercurrent 
events before week 26, this leads to an assumption of a mean treatment difference of 0.015%-point 
for the specified estimand in the overall population.  
The SD is assumed to be 1.0%-point based on results from studies with insulin degludec in subjects 
treated with basal in sulin (NN1250-3998).  
From the above assumptions and requirements, [ADDRESS_124074]. This will ensure sufficient power (90%) of confirming non- inferiority.  
Assuming 25% screening failures, approximately [ADDRESS_124075].  
This sample size appears to be reasonable also under deviations from the assumed treatment 
difference as illustrated in Table 9-1
 displaying power for various alternative treatment differences 
and SD . 
For the hypothesis of superiority of insulin icodec compared to insulin degludec in terms of change 
from baseline to week  26 in HbA 1c, there will be 49% marginal power and also 49% combined 
power to detect if the true treatment difference in HbA 1c is 0.18%-point with the sample size of 520. 
Table 9-1 Power for various treatment differences and SDs. 
SD 
(%-point)   
 
0.003  Treatment difference  
(%-point)  
0.015   
 
0.03 
0.9 96% 95% 93% 
1.0 92% 90% 87% 
1.1 87% 84% 80% 
SD: Power is computed for 1:1 randomisation and 520 subjects randomised.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  52 of 100 
 
9.3 Populations for analyses 
The following populations  are defined: 
Population  Description  
Randomised  All subjects randomised  
Full analysis set  Full analysis set: All subjects randomised. Subjects will be analysed according to 
the randomised treatment.  
Safety  analysis set  All subjects randomly assigned to trial treatment and who take at least [ADDRESS_124076]. Subjects are analysed according to the treatment they actually 
received.  
In exceptional cases, subjects or observations may be eliminated from the full analysis set. In such 
case the reasons for their exclusion will be documented before unblinding. The subjects and 
observations excluded from analysis sets, and the reason for this, will be described in the clinical 
trial report . 
The following periods will be considered for the data collected:  
In-trial period  
The in -trial period starts at randomisation and ends at the date of: 
• The last direct subject -site contact  
• Withdrawal for subjects who withdraw their informed consent 
• The last subject -investigator contact [CONTACT_36330]-up (i.e. possibly an unscheduled phone visit) 
• Death for subjects who die before any of the above 
For subjects not randomised but exposed to trial product the in- trial period starts at the date of first 
dose of trial product. The end date is as defined as above.  
On-treatment period  
The on-treatment period starts at the date of first dose of trial product as recorded on the eCRF, and 
ends at the first date of any of the following: 
• The end of trial visit ( V30) 
• The last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly 
insulin  (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) 
• The end -date for the in -trial observation period 
The on-treatment period represents the time period in which a subject is considered exposed to trial 
product. 
All efficacy endpoints will be summarised and analysed using the full analysis set and the ‘in- trial’  
period. Safety endpoints will be evaluated using the on- treatment period with descriptive statistics 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  53 of 100 
 
being based on the safety analysis set (SAS) and statistical analyses being based on the full analysis 
set unless otherwise specified. 
9.4 Statistical analyses 
The statistical analysis plan (SAP) will be finalised prior to first subject first visit, and it will 
include a more technical and detailed description of the statistical analyses described in this section.  
This section is a summary of the planned statistical analyses of the most important endpoints including primary and secondary endpoints. 
9.4.1 General considerations  
Presentation of results from a statistical analysis will include the estimated mean treatment 
difference (or ratio) presented together with the two -sided 95% confidence interval and the 
corresponding two- sided p -value.  
In the statistical models, explanatory factors will be coded as follows: 
• Treatment: Once weekly insulin icodec, insulin degludec  
• Region: Asia, Europe, North America, Africa  
The r egions will be defined as follows:  
• Asia: Japan, South Korea 
• Europe: Bulgaria, [LOCATION_013], P oland, Portugal, Ukraine 
• North America: [LOCATION_002]  
• Africa: South Africa  
The last available assessment made prior to the first dose will be used as the baseline value.  
All endpoints based on CGM measurements will be derived the following way. The percentage of time spent in a given glycaemic range will be calculated as [ADDRESS_124077] 70% of the planned CGM 
measurements during the last four weeks of treatment are available for endpoint data to be included 
in the analys is.
20 
9.4.2 Primary endpoint  
The primary  endpoint is change in HbA 1c from baseline to week 26. 
The ‘treatment policy’ estimand, will be estimated based on the full analysis set using all HbA 1c 
measurements obtained at the week 26 visit, especially including measurements from subjects 
discontinuing their randomised treatment or initiating treatment with bolus insulin for more than 2 weeks. Missing HbA
1c values at the week 26 visit (regardless of treatment completion status) will 
be imputed from trial participants, who have discontinued their randomised treatment or initiated 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124078]: 
• First, one thousand (1000) copi[INVESTIGATOR_111360] H bA1c.  
• Second, for subjects who discontinued their randomised treatment or initiated treatment with 
bolus insulin for more than [ADDRESS_124079]  available planned on-
treatment without initiation of treatment with bolus insulin for more than 2 weeks (LAOT -
WOB) value to the week 26 visit will be analysed for each dataset copy using an analysis of 
covariance (ANCOVA) model with randomised treatment as fixed factor and LAOT- WOB 
value and the time point (study day) of this assessment as covariates. The estimated parameters, and their variances, from the model will be used to impute missing HbA
1c values 
for the change from LAOT- WOB to the week 26 visit and subsequently the missing HbA 1c 
value at the week 26 visit. 
• For each of the complete data sets, the primary endpoint will be analysed using an ANCOVA 
model with region and randomised treatment as fixed factors, and baseline HbA 1c as a 
covariate. The esti mates and SDs for the 1000 data sets will be pooled to one estimate and 
associated SD using Rubin’s rule.[ADDRESS_124080] similarly as subjects that discontinue randomised treatment or initiate treatment with bolus insulin for more than 
2 weeks.  
If non -inferiority is confirmed, i.e. if the 95% CI is strictly below 0.3%, then the primary endpoint 
will further be tested for superiority. Superiority for change in HbA
1c will be considered confirmed 
if the 95% CI is strictly below zero.  
The following sensitivity analysis evaluating the robustness of the assumptions about the missing 
data will be carried out:  
For the primary endpoint, a two-dimensional tippi[INVESTIGATOR_111361]
1c measurement at the week [ADDRESS_124081] a worse 
outcome in the insulin icodec arm and a better outcome in the insulin degludec arm compared to what was imputed in the primary analysis. This is done by [CONTACT_111423] Δ
i to the 
imputed HbA 1c values before analysing the data. The value of Δ i will be varied independently in the 
two treatment arms. The non-inferiority margin of 0.3% will be among the Δi values investigated. 
The plausibility of the values of Δ i where the conclusion of the primary analysis change will be 
evaluated to assess the robustness of the primary analysis result. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  55 of 100 
 
9.4.3 Secondary endpoints  
[IP_ADDRESS] Confirmatory secondary endpoi nt 
Not applicable for this trial.  
[IP_ADDRESS] Supportive secondary endpoints  
Supportive secondary endpoints will be evaluated in the framework of the primary estimand. 
Efficacy endpoints  
Change in fasting plasma glucose (FPG) from baseline week 0 (V2) to week 26 (V28) 
Missing FPG values at the week 26 visit (regardless of treatment completion status) will be imputed 
from trial participants who are from the insulin degludec group, and who have completed and 
adhered to their randomised insulin treatment without initiatio n of bolus insulin treatment for more 
than 2 weeks at any time prior to the week 26 visit – i.e., data will be imputed based on the assumption that subjects with missing endpoint data will behave like subjects completing the insulin 
degludec treatment without initiation of bolus insulin treatment for more than 2 weeks at any time 
prior to the week 26 visit. Specifically, the imputations and analyses will be carried as follows: 
• First, one thousand (1000) copi[INVESTIGATOR_111362]. 
• Second, for each dataset copy, an analysis of covariance (ANCOVA) model with a baseline 
value as a covariate will be fitted to FPG values for subjects who completed their randomised 
treatment without initiation of bolus insulin treatment for more than 2 we eks at any time prior 
to the week 26 visit in the insulin degludec group. The estimated mean, and variances, from the model will be used to impute missing values in both treatment groups. 
• For each of the completed data sets, the endpoint will be analysed using an ANCOVA model 
with region and randomised treatment as fixed factors and a baseline value as a covariate. The 
estimates and SDs for the 1000 data sets will be pooled to one estimate and associated SD 
using Rubin’s rule.
21 
Time in target range 3.9-10.0 mmol/L (70-180 mg/dL), from week 22 (V24) to week 26 (V28) 
Time in target range 3.9 -10.0 mmol/L (70-180 mg/dL) from week 22 to week 26 will be analysed 
using the same model as specified for change in FPG, but without using the baseline value as a 
covariate.  
Change in DTSQs (Diabetes Treatment Satisfaction Questionnaire) in total treatment satisfaction from baseline week 0 (V 2) to week 26 (V28) 
The change in DTSQs in total treatment satisfaction from baseline to week 26 will be analysed using the same model as specified for change in FPG, but the corresponding baseline value will be 
used as a covariate.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  56 of 100 
 
Safety endpoints  
Hypogl ycaemic epi[INVESTIGATOR_111363]: 
• Number of severe hypoglycaemic epi[INVESTIGATOR_1841] (level 3) from baseline week 0 (V2) to week 31 
(V30) 
• Number of clinically significant hypoglycaemic epi[INVESTIGATOR_1841] (level 2) (<3.0 mmol/L (54 mg/dL), 
confirmed by [CONTACT_41132]) from baseline week 0 (V2) to week 31 (V30) 
• Number of clinically significant hypoglycaemic epi[INVESTIGATOR_1841] (level 2) (<3.0 mmol/L (54 mg/dL), 
confirmed by [CONTACT_41132]) or severe hypoglycaemic epi[INVESTIGATOR_1865] s (level 3) from baseline week 0 
(V2) to week 31 (V30) 
For subjects who discontinued their randomised treatment, the number of epi[INVESTIGATOR_111364] (time of follow-up 2 (V30) to planned end of the on- treatment period) will be imputed using 
a multiple imputation technique, assuming that the event rate pre follow-up 2 (V30) follows the respective treatment groups rate whilst post follow-up 2 (V30) event rate is the rate of the insulin 
degludec group. The imputation will be done as follows: 
• First, a Bayes negative binomial model with log- link function will be fitted to the event rate 
data to obtain the posterior distribution of model parameters. The model will include region and randomised treatment as fixed factors and the logarithm of the on- treatme nt period as 
offset.  
• Second, based on the estimated parameters for the insulin degludec group in this model, the 
number of epi[INVESTIGATOR_111365]. Multiple copi[INVESTIGATOR_014] (1000 copi[INVESTIGATOR_014] ) of a complete data set will be generated 
by [CONTACT_111424].  
• For each of the complete data sets, the number of epi[INVESTIGATOR_111366] a negative 
binomial model with log -link, fixed factors and offset as described in step 1. The estimates and 
SDs for the 1000 data sets will be pooled to one estimate and associated SD  using Rubin’s 
rule.
21 
For the definition and classification of hypoglycaemic epi[INVESTIGATOR_111367] 7 (Section 10.7). 
Time spent < 3.0 mmol/L (54 mg/dL) and time spent > 10 mmol/L (180 mg/dL) from week 22 (V24) to week 26 (V28) 
Time spent < 3.0 mmol/L (54 mg/dL) (below range) and time spent > 10 mmol/L (180 mg/dL) 
(above range) from week [ADDRESS_124082] 0% time spent, then an alternative analysis will  be performed either 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  57 of 100 
 
considering the endpoint as a dichotomous endpoint or by [CONTACT_2931] a censored analysis of the log-
transformed values. Further details will be provided in the SAP. 
Mean weekly insulin dose from week 24 (V26) to week 26 (V28) 
Mean weekly insulin dose during the last 2 weeks of treatment (from week 24 to 26) will be log-
transformed and analysed using the same model as specified for change in FPG, but with using the 
log-transformed weekly insulin dose at screening as a covariate. 
Change in b ody weight from baseline week 0 (V2) to week 26 (V28) 
Change in body weight from week [ADDRESS_124083] safety assessments ( SAEs , 
AEs, safety laboratory parameters, vital signs, etc.) will be reported descriptively based on the 
on-treatment period ; including any notable changes of clinical interest in laboratory parameters. In 
addition, SAEs will be reported descriptively based on the in- trial period.  
9.4.6 Other analyses   
For other analyses,  please refer to the SAP.  
[IP_ADDRESS] Pharmacokinetic modelling  
Insulin icodec serum concentration data will be used for population PK analysis. The obje ctive of 
the population PK analysis is to evaluate the effects of pre- specified covariates on serum 
concentrations of insulin icodec. 
The population PK analysis will be performed by [CONTACT_111425], Novo 
Nordisk. A more technical and detailed elaboration of the population PK analysis will be given in a 
modelling analysis plan, which will be prepared before database lock . In brief, a previously 
developed PK model for insulin icodec will be applied. The absorption rate constant (Ka) in the model will be fixed, and the apparent clearance (CL/F) and the apparent volume of distribution 
(V/F) will be re -estimated. The covariates of interest will be incorporated into the PK model using 
criteria which will be specified in the modelling analysis pl an. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  58 of 100 
 
The population PK analysis will be reported in a separate modelling report, which will not be part 
of the clinical trial report. The individual insulin icodec serum concentration data will be tabulated 
in the bioanalytical report. 
9.5 Interim analyses  
Not applicable for this trial.  
9.6 Data monitoring committee  
Not applicable for this trial.  
9.7 Reporting of the main part of the trial  
Not applicable for this trial. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  59 of 100 
 
10 Supporting documentation and operational considerations  
10.1 Appendix 1: Regulatory, ethical, and trial oversight considerations 
10.1.1 Regulatory and ethical considerations 
This trial will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the Declaration of 
Helsin ki22 and applicable ICH good c linical practice (GCP) Guideline23. 
• Applicable laws and regulations. 
• The protocol, informed consent form, investigator’s brochure (as applicable) and other relevant 
documents (e.g. advertisements) must be submitted to an IRB/IEC and reviewed and approved 
by [CONTACT_1201]/IEC before the trial is initiated.  
• Regulatory authorities will receive the clinical trial application, protocol amendments, reports 
on SAEs, and the clinical trial report according to national requirements. 
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the trial design, except for changes necessary to eliminate an immediate 
safety hazard to trial subjects.  
• Before a site is allowed to start screening subjects, written notifica tion from Novo Nordisk must 
be received.  
• The investigator will be responsible for: 
o providing written summaries of the status of the trial annually or more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_5040]/IEC a nd/or regulatory authorities 
o notifying the IRB/IEC of SAEs or other significant safety findings as required by [CONTACT_1744]/IEC procedures 
o providing oversight of the conduct of the trial at the site and adherence to requirements of ICH guidelines, the IRB/IEC, and all other applicable local 
regulations 
o ensuring submission of the clinical trial report synopsis to the IRB/IEC 
o reporting any potential serious breaches to the sponsor immediately after discovery 
10.1.2 Financial disclosure  
Investigators and sub- investigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the trial and one 
year after completion of the trial.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  60 of 100 
 
10.1.3 Informed consent process  
• The investigator or his/her representative will explain the nature of the trial to the subject and 
answ er all questions regarding the trial.  
• The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial.   
• Subjects must be informed that their participation is voluntary. 
• Subjects must be informed about their privacy rights.  
• Subjects will be required to sign and date a statement of informed consent that meets the 
requirements of local regulations, ICH guidelines23, Declaration of Helsinki22 and the IRB/IEC 
or site.  
• The medical record must include a statement that written informed consent was obtained before 
any trial related activity and the date when the written consent was obtained. The authorised 
person obtaining the informed consent must also sign and date the informed consent form 
before any trial related activity.  
• The responsibility of seeking informed consent must remain with the investigator, but the 
investigator may delegate the tas k to a medically qualified person, in accordance with local 
requirements.  
• Subjects must be re-consented to the most current version of the informed consent form (s) 
during their participation in the trial.  
• A copy of the informed consent form (s) must be provided to the subject.  
10.1.[ADDRESS_124084] may 
receive a “welcome to the trial letter” and a “thank you for your participation letter” after completion of the trial. Further, the subject may receive other w ritten information during the trial.  
All written information to subjects must be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_111368]. 
10.1.5  Data protection 
• Subjects will be a ssigned a 6-digit unique identifier, a subject number. Any subject records or 
datasets that are transferred to Novo Nordisk will contain the identifier only. No direct 
identifiers from the subject are transferred to Novo Nordisk. 
• The subject and any biological material obtained from the subject will be identified by [CONTACT_41163], visit number and trial ID. Appropriate measures such as encryption or leaving out certain identifiers will be enforced to protect the identity of subjects as required by [CONTACT_5737], 
regional and national requirements.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  61 of 100 
 
• The subject must be informed about his/her privacy rights, including that his/her personal trial 
related data will be used by [CONTACT_18023]. The 
disclosure of the data must also be explained to the subject.  
• The subject must be informed that his/her medical records may be examined by [CONTACT_18024], by [CONTACT_6667]/IEC members, and 
by [CONTACT_6668].  
10.1.6 Committees structure  
[IP_ADDRESS] Novo Nordisk safety committee 
Novo Nordisk will perform ongoing safety surveillance. If new safety signals are identified, these 
will be evaluated by [CONTACT_18025].  
[IP_ADDRESS] Trial safety group 
Not applicable for this trial.  
[IP_ADDRESS] Data monitoring committee 
Not applicable for this trial.  
[IP_ADDRESS] Event adjudication committee  
An independent external EAC is established to perform ongoing blinded adjudication of selected AEs and deaths (see Table 8-1
). 
The EAC will evaluate events sent for adjudication using pre-defined definitions and guidelines in accordance with the EAC charter. The evaluation is based on review of pre- defined clinical data 
collected by [CONTACT_30107]. The EAC is composed of permanent members covering all required medical specialities. EAC members must disclose any potential conflicts of interest and must be independent 
of Novo Nordisk. The EAC will have no authority to impact trial conduct, trial protocol or 
amendments. The assessments mad e by [CONTACT_111426].  
10.1.7 Dissemination of clinical trial data  
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk- trials.com. It will also 
be disclosed according to other applicable requirements, such as those of the International 
Committee of Medical Journal Editors (ICMJE)
24, the Food and Drug Administration Amendment 
Act (FDAAA)25, European Commission Requirements1, 26, [ADDRESS_124085] at 
these web sites, Novo Nordisk may disclose the investigator’s contact [CONTACT_18026]. As a result of increasing requirements for transparency, some countries require public disclosure of 
investigator names and their affiliations.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  62 of 100 
 
The primary completion date (PCD) is the last assessment of the primary endpoint, and is for this 
trial last subject first treatment  + [ADDRESS_124086] completed visit V28. The PCD determines the deadline for results disclosure at clinic altrials.gov according to 
FDAAA.  
10.1.8 Data quality assurance 
[IP_ADDRESS] Case report forms  
• Novo Nordisk or designee is responsible for the data management of this trial including quality 
checking of the data.  
• All subject data relating to the trial will be recorded on electronic CRFs (eCRFs)  unless 
transmitted electronically to Novo Nordisk (e.g. laboratory and eDiary data) or when applicable on paper CRF. The investigator is responsible for verifying that data entries are 
accurate and correct by [CONTACT_111427]. 
• The following will be provided as paper CRFs:  
o Pregnancy forms 
• The following will be provided as paper CRFs to be used when access to the eCRF is revoked 
or the eCRF is temporarily unavailable: 
o Adverse event  forms   
o Safety information  forms  
o Technical complaint forms (also to be used to report complaints on trial product not yet allocated to a subject)  
• Corrections to the CRF data may be made by [CONTACT_36322]’s delegated 
staff. An audit trail will be maintained in the CRF application containing as a minimum: the old and the new data, identification of the person entering the data, date and time of the entry 
and reason for the correction. If corrections are made by [CONTACT_093]’s delegated staff aft er 
the date when the investigator signed the CRF, the CRF must be signed and dated again by [CONTACT_093]. 
• The investigator must ensure that data is recorded in the CRF as soon as possible, preferably 
within 5 working days after the visit. Once data has been entered, it will be available to Novo 
Nordisk for data verification and validation purposes.  
[IP_ADDRESS] Monitoring  
• The investigator must permit trial-related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents (original documents, 
data and records). Direct access includes permission to examine, analyse, verify and reproduce 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124087](s) and report(s) that are important to the evaluation of the trial. If the electronic 
medical record does not have a visible audit trail, the investigator must provide the monitor 
with signed and dated printouts. In addition, the relevant site staff should be available for 
discussions at monitoring visits and between monitoring visits (e.g. by [CONTACT_756]).  
• Trial monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by [CONTACT_18029], complete and verifiable from source documents; that the safety and rights of subjects are being protected, to monitor drug 
accountability and collect completed paper CRF pages, if applicable, and that the trial is being 
conducted in accordance with the currently approved protocol and any other trial agreements, ICH GCP, and all applicable regulatory requirements. 
• Monitoring will be conducted using a risk-based approach including risk assessment, 
monitoring plans, centralised monitoring (remote assessment of data by [CONTACT_3454]) and visits to sites.   
• Monitors will review the subject’s medical records and other source data to  ensure consistency 
and/or identify omissions compared to the eCRF.  
[IP_ADDRESS] Protocol compliance 
Deviations from the protocol should be avoided. If deviations do occur, the investigator must inform the monitor without delay and the implications of the deviation must be reviewed and 
discussed. 
Deviations must be documented and explained in a protocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed vi a edit checks in the eCRF or via listings from the trial database.  
10.1.[ADDRESS_124088] be verifiable in source documentation, except for the following 
data that has been transferred directly into the database and will be considered sourc e data:  
• For e.g. electronic patient reported outcomes , eDiary, data in the service providers’ database is 
considered source data.  
• Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data coll ected. Source documents are filed at the site.  
• Data reported on the paper CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents, or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records. 
Also, current medical records must be available.  
• It must be possible to verify subject’s medical history in source documents, such as subject’s 
medical record.  
• The investigator must document any attempt to obtain external medical information by [CONTACT_41175](s) when information was requested, and who was contact[INVESTIGATOR_530]. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  64 of 100 
 
• Definition of what constitutes source data can be found in a source document agreement at each 
site. There will only be one source doc ument defined at any time for any data element.  
10.1.10 Retention of clinical trial documentation  
• Records and documents, including signed informed consent forms, pertaining to the conduct of 
this trial must be retained by [CONTACT_1732] 15 years after end of trial unless local 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of Novo Nordisk. No 
records may be transferred to another location or party without written notification to Novo 
Nordisk.  
• The investigator must be able to access his/her trial documents without involving Novo Nordisk 
in any way. If applicable, electronic CRF (eCRF) and other subject data will be provided in an 
electronic readable format to the investigator before access is revoked to the systems supplied 
by [CONTACT_3454]. Site -specific CRFs and other subject data (in an electronic readable format 
or as paper copi[INVESTIGATOR_17951]) must be retained by [CONTACT_779]. A copy of all data will be stored by 
[CONTACT_3454]. 
• Subject’s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.  
10.1.[ADDRESS_124089] 
inform the subjects promptly and ensure appropriate therapy and follow-up. The investigator and/or 
Novo Nordisk must also promptly inform the regulatory authorities and IRBs/IECs and provide a 
detailed written explanation.  
Sites will be closed upon trial completion. A site is considered closed when all required documents and trial supplies have been collected and a site closure visit has been performed. 
The investigator may initiate site closure at any time, provided there is reason able cause and 
sufficient notice is given in advance of the intended termination. Reasons for the early closure of a site by [CONTACT_41177]:  
• failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local 
health authorities, Novo Nordisk procedures or GCP guidelines 
• inadequate recruitment of subjects by [CONTACT_093] 
• discontinuation of further trial product development. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124090] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the site. If any tasks are delegated, the investigator must 
maintain a log of appropriately qualified persons to whom he/she has delegated spe cified trial -
related duties. The investigator must ensure that there is adequate and documented training for all staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects.  
A qualified physician, who is an investigator or a sub investigator for the trial, must be responsible 
for all trial- related medical decisions.   
The investigator is responsible for filing essential documents (i.e. those documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents, including the subject identification 
code list must be kept in a secure locked facility so that no unauthorized persons can get access to 
the data.   
The investigator will take all necessary technical and organisational safety measures to prevent accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organis ational safety measures have been taken.  
During any period of unavailability, the investigator must delegate responsibility for medical care of subjects to a specific qualified physician who will be readily available to subjects during that time.  
If the in vestigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.  
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s). 
10.1.[ADDRESS_124091] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.   
Novo Nordisk assumes no liability in the event of negligence or any other liability of the sites or investigators conducting the trial or by [CONTACT_18033].  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124092], if deemed necessary by [CONTACT_3454]. 
Provided that certain conditions are fulfilled, Novo Nordisk may grant access to information 
obtained during this trial to researchers who require access for research projects studying the same 
disease and/or trial product studied in this trial.  
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.  
One or two investigators will be appointed by [CONTACT_36345]  (signatory investigator) on behalf of all participating investigators. 
[IP_ADDRESS] Communication of results  
Novo Nordisk commits to communicate and disclose results of trials regardless of outcome. Disclosure includes publication of a manuscript in a peer- reviewed scientific journal, abstract 
submission with a poster or oral presentation at a scientific meeting or disclosure by [CONTACT_11174]. 
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations. Novo Nordisk reserves the right to defer the release of data 
until specified milestones are reached, for example when the clinical trial report is available. This 
includes the right not to release the results of interim analyses, because the release of such information may influence the results of the entire trial.  
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_093](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_124093] intellectual property. 
In all cases, the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. In the event of any disagreement on the 
content of any publication, both the investigators’ and Novo Nordisk opi[INVESTIGATOR_17952]. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  67 of 100 
 
[IP_ADDRESS] Authorship  
Novo Nordisk will work with one or more investigator(s) and other experts who have contributed to 
the trial concept or design, acquisition, analysis or interpretation of data to report the results in one 
or more publications. 
Authorship of publications should be in accordance with the Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals by [CONTACT_18037].28 
All authors will be provided with the relevant statistical tables, figures, and reports needed to evaluate the planned publication.  
Where required by [CONTACT_18038], the investigator from each site will be named in an 
acknowledgement or in the supplementary material, as specified by [CONTACT_18038].  
[IP_ADDRESS] Site-specific publication(s) by [CONTACT_1697](s)  
For a multicentre clinical trial, analyses based on single -site data usuall y have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by [CONTACT_3454]. Thus, Novo Nordisk may deny a 
request or ask for deferment of the publication of individual site results until the primary manuscript 
is accepted for publication. In line with Good Publication Practice, such individual reports should 
not precede the primary manuscript and should always reference the primary manuscript of the trial.  
[IP_ADDRESS] Investigator access to data and review of results 
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access to the database.  
Individual investigators will have their own research subjects’ data and will be provided with the randomisation code after results are available.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  68 of 100 
 
10.2 Appendix 2: Clinical laboratory tests  
• The tests detailed in Table 10-1 and Table 10-2  will be performed by [CONTACT_2237]. 
• Additional tests may be performed at any time during the trial as determined necessary by [CONTACT_41161]. Only laboratory samples specified in the protocol 
should be sent to the central laboratory for analysis; if additional laboratory sampling is 
needed, e.g. to follow-up on AEs, this must be done at a local laboratory. 
• The central lab will communicate to the investigator abnormal values of parameters not 
requested in the protocol but identified by [CONTACT_111428]/or their processes 
according to their lab SOPs. These data will not be transferred to the trial database. The 
investigator should review such values for AEs and report these according to this protocol. 
• The investigator must review all laboratory results for concomitant illnesses  and AEs. 
• Laboratory samples will be destroyed no later than at finalisation of the clinical trial report, 
except the following:  
• For haematology samples (differential count) where the test result is not normal, then a part of the sample may be kept for up to two years or according to local regulations.  
• Human biosamples for retention will be stored as described in Appendix 6 (Section 10.6
). 
Table 10-1 Protocol- required efficacy laboratory assessments  
Laboratory 
assessments  Parameters  
Glucose metabolism  
(V2, V12, V20, V28)  • Fasting plasma glucose  (FPG)1 
• HbA 1c (also at V1 and V28A ) 
NOTE:  
1An FPG result < 3.9 mmol/L (70 mg/dL) in relation to planned fasting visits should not be reported as a 
hypoglycaemic  epi[INVESTIGATOR_111369] (Appendix 3, Section 10.3). 
A FPG result >16.7 mmol/L (300 mg/dL) should not be reported as a hyperglycaemic epi[INVESTIGATOR_111370] ( Appendix 3, Section 10.3). 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  69 of 100 
 
Table 10-2 Protocol- required safety laboratory assessments  
Laboratory  
 assessments  Parameters  
Haematology  
(V1, V12, V28)  • Erythrocytes  
• Haematocrit  
• Haemoglobin  
• Leucocytes  
• Thrombocytes  
• Basophils   
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  
Biochemistry1  
(V1, V12, V28)  • Alanine Aminotr ansferase  
• Albumin  
• Alkaline phosphatase  
• Aspartate Aminotransferase 
• Creatinine  
• Potassium  
• Sodium  
• Total bilirubin  
Lipi[INVESTIGATOR_805]  
(V2, V12, V28)  • Cholesterol  
• High density lipoprotein (HDL) cholesterol  
• Low density lipoprotein (LDL) cholesterol  
• Triglycerides  
• Free fatty acids  
Pregnancy Testing  
(V2, V28, V30)  • Highly sensitive urine human chorionic gonadotropin (hCG) pregnancy test (as 
needed for women of childbearing potential)2 
Other tests   • eGFR calculated by [CONTACT_41162] -EPI [INVESTIGATOR_10908], eGFR is for screening purposes only  
• In case of systemic hypersensitivity (Section 8.9.2 ): Tryptase (optimal 0.5- [ADDRESS_124094] the hypersensitivity reaction), total IgE antibodies, anti- insulin icodec IgE 
antibodies, anti -insulin icodec binding antibodies, anti -human insulin IgE antibodies.  
• anti-insulin icodec antibodies (V2, V4, V8, V12, V20, V28, V30)  
• insulin -icodec serum concentration (V4, V8, V12, V20, V28, V30)  
Notes:  
1Details of required actions for increased liver parameters  are given in Section 10.3.2  (Hy’s Law). 
2Local urine testing will be standard unless serum testing is required by [CONTACT_18039]/IEC.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  70 of 100 
 
10.3 Appendix 3: Adverse events: Definitions and procedures for recording, evaluation, 
follow- up, and reporting  
10.3.[ADDRESS_124095] (IMP), whether or not considered related to 
the IMP.  
An AE can therefore be any unfavourable  and unintended sign, including an abnormal laboratory 
finding, symptom or disease (new or exacerbated) temporally associated w ith the use of an IMP.  
 
Events meeting  the AE definition  
• Any abnormal laboratory test results or safety assessments considered clinically significant in 
the medical and scientific judgment of the investigator, including events that have worsened from pri or to the time point from which AEs are collected  
• Conditions detected or diagnosed after IMP administration even though it may have been 
present prior to the time point from which AEs are collected  
• Exacerbation/worsening of a chronic or intermittent condition including either an increase in 
frequency and/or intensity of the condition 
• Signs, symptoms or the clinical sequelae of a suspected drug-drug interaction 
• Signs, symptoms or the clinical sequelae of a suspected overdose of IMP regardless of intent 
A "lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE 
if they fulfil the definition.  
Events NOT  meeting the AE definition  
• Conditions present prior to the time point from which AEs are collected and anticipated day -
to-day fluctuations of these conditions, including those identified during screening or other 
trial procedures performed before exposure to IMP.  
• Note: Conditions present or occurring prior to the time point from which AEs are collected 
should be recorded as concomitant illness/medical history. 
• Medical or surgical procedures (e.g. endoscopy, appendectomy). The condition that leads to 
the procedure is the AE.  
• Medical or surgical procedures not preceded by [CONTACT_18040] a known condition.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124096] one  of the following criteria:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_15574]  
• Hospi[INVESTIGATOR_17953]/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_17954]. If a complication prolongs hospi[INVESTIGATOR_17955], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_11956]” occurred or was necessary, the AE should be considered serious. 
• Hospi[INVESTIGATOR_17956] (e.g. elective medical or surgical procedures) of a 
condition that was present prior to the time point from which AEs are collected, and that did not worsen, is not considered an AE. 
Note:  
• Hospi[INVESTIGATOR_17957], trial related, social and convenience reasons do not 
constitute AEs and should therefore not be reported as AEs or S AEs.   
• Hospi[INVESTIGATOR_111371], planned before trial inclusion, are not 
considered AEs or SAEs.  
d. Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions. 
• This definition is not intended to include experience of relatively minor medical significance, 
such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g. sprained ankle), which may interfere with or prevent everyday life functions but 
do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Important medical event:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations. This includes important medical events that may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_111372]. These events should usually be considered serious and reported as SAEs using the important medical event criterion. 
• The following adverse events must always be reported as SAEs using the important medical 
event criterion if no other seriousness criteria are applicable: 
• Suspi[INVESTIGATOR_17960]  
• Risk of liver injury defined as alanine aminotransferase or aspartate 
aminotransferase >3  x UNL and total bilirubin >2 x UNL where no alternative aetiology 
exists (Hy's law)  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  72 of 100 
 
 
10.3.3 Description of events for adjudication and AEs requiring additional data collection  
Description of events for adjudication  and AEs requiring additional data collection (on 
specific event form)  
Events for adjudication  
An event for adjudication is a selected AE or death evaluated by [CONTACT_111420] 
a blinded manner, please refer to Table 8-1 Appendix 1 (Section [IP_ADDRESS]) and Figure 10-1 . 
• Death  
• All cause death  
• Acute coronary syndrome 
• All types of acute myocardial infarction and unstable angina pectoris requiring 
hospi[INVESTIGATOR_11956]  
• Cerebrovascular event (stroke or transient ischemic attack)  
• Epi[INVESTIGATOR_111373], spi[INVESTIGATOR_1831], or retinal vascular injury as a result of haemorrhage or ischemia, with or without infarction  
• Heart failure (requiring hospi[INVESTIGATOR_111347])  
• New epi[INVESTIGATOR_111374], unscheduled hospi[INVESTIGATOR_111375]/office/emergency department visit 
Adverse events requiring additional data collection  
AEs requiring additional data collection on a specific event form. 
Injection site reaction  
If an event of injection site reaction is observed, additional information must be obtained if 
available on a separate form . 
Hypersensitivity  
Systemic hypersensitivity can be manifested as isolated symptoms such as urticaria, angioedema, conjunctivitis, rhinitis, bronchospasm, gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain), or as anaphylaxis or anaphylactic shock. 
Anaphylaxis is an acute, potentially lethal, multisystem syndrome resulting from the sudden 
release of mast cell - and basophil -derived mediators into the circulation
29. It most often results 
from immunologic reactions to foods, medications, and insect stings, although it can also be induced through nonimmunologic mechanisms by [CONTACT_111429] a sudden, systemic degranulation of mast cells or basophils
30. Characteristic symptoms and signs, occurring 
minutes to a few hours after exposure to potential triggering agents or events may include: flush ing, urticaria, angioedema, hoarseness, throat tightness, stridor, wheezing, coughing, 
shortness of breath, abdominal pain, vomiting, and/or hypotension, dizziness or collapse.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  73 of 100 
 
Local hypersensitivity reactions, including rash, redness, pruritus and oedema, may occur at the 
site of investigational drug injection. 
Drug hypersensitivity reactions (DHRs) are the adverse effects of pharmaceutical formulations 
(including active drugs and excipi[INVESTIGATOR_840]) that clinically resemble allergy31. The y can be allergic and 
non-allergic.  
If a hypersensitivity event is suspected, the subjects must contact [CONTACT_111430]. All events must be reported, and in case of systemic hypersensitivity, additional information must be provided on a separate form .
 
Medication error  
A medication error is an unintended failure in the IMP treatment process that leads to, or has the potential to lead to, harm to the subject, such as:  
• administration of wrong drug.  
Note: Use of wrong DUN is not considered a medication error unless it results in administration of wrong drug.  
• wrong route of administration, such as intramuscular instead of subcutaneous  
• accidental administration of a lower or  higher dose than intended. The administered dose 
must deviate from the intended dose to an extent where clinical consequences for the trial subject were likely to happen as judged by [CONTACT_093], although they did not necessarily occur.  
• missed doses or drug pauses are not to be reported as a medication error. 
Misuse and abuse   
• Situations where the IMP is intentionally and inappropriately used not in accordance with the 
protocol (e.g. overdose to maximise effect) 
• Persistent or sporadic, intentional excessive use of an IMP which is accompanied by [CONTACT_18041] (e.g. overdose with the intention to cause harm) 
Medication error, misuse and abuse must always be reported as an AE (e.g. accidental overdose, intentional overdose or other) on a separate AE form, and a medication error, misuse and abuse form must be completed. In case of a medication error and/or misuse and abuse resulting in a 
clinical consequence, this must be reported on an additional AE form.  
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  74 of 100 
 
10.3.4 Recording and follow- up of AE and/or SA E 
AE and SAE recording  
• The investigator will record all relevant AE/SAE information in the CRF.  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE. 
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospi[INVESTIGATOR_1088], laboratory and diagnostics reports) related to the event.  
• There may be instances when copi[INVESTIGATOR_14168] (e.g. medical records) for certain 
cases are requested by [CONTACT_3454]. In such cases, all subject identifiers, with the exception of the subject number, will be redacted on the copi[INVESTIGATOR_111376]. 
• For all non-serious AEs, the applicable forms should be signed when the event is resolved or 
at the end of the trial at the latest. For sign -off of SAE related forms, refer to “AE and SAE 
reporting vi a paper CRF” later in this section.  
• Novo Nordisk products used as concomitant medication or NIMP: if an AE is considered to 
have a causal relationship with a Novo Nordisk marketed product used as or NIMP or  
concomitant medication in the trial, it is important that the suspected relationship is reported to Novo Nordisk, e.g. in the alternative aetiology section on the safety information form. 
Novo Nordisk may need to report this adverse event to relevant regulatory authorities . 
 
Assessment of severity  
The investigator will assess severity for each event reported during the trial and assign it to one of 
the following categories:  
• Mild : An event that is easily tolerated by [CONTACT_423], causing minimal discomfort and not 
interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities.  
• Severe: An event that prevents normal everyday activities.  
Note: An AE that is assessed as severe should not be confused with a SAE. Both AEs and 
SAEs can be assessed as severe.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  75 of 100 
 
Assessment of causality  
• The investigator is obligated to assess the relationship between IMP and the occurrence of 
each AE/SAE.  
• Relationship between an AE/SAE and the relevant IMP(s) should be assessed as: 
• Probable - Good reason and sufficient documentation to assume a causal relationship. 
• Possible - A causal relationship is conceivable and cannot be dismissed. 
• Unlikely - The event is most likely related to aetiology other than the IMP. 
• Alternative aetiology, such as underlying disease(s), concomitant medication, and other risk 
factors, as well as the temporal relationship of the event to IMP administration, will be 
considered and investigated. 
• The investigator should use the Investigator’s Brochures for insulin icodec and insulin 
degludec for the assessment. For each AE/SAE, the investigator must document in the 
medical records that he/she has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred, and the invest igator has minimal 
information to include in the initial report. However, it is important that the investigator always makes an assessment of causality for every event before the initial transmission of the SAE data.  
• The investigator may change his/her opi[INVESTIGATOR_17963], in light of follow-up information, 
and update the causality assessment in the CRF.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.   
Final outcome  
The investigator will select the most appropriate outcome:  
• Recovered/resolved:  The subject has fully recovered, or by [CONTACT_18043] 
• Recovering/resolving:  The condition is improving, and the s ubject is expected to recover 
from the event. This term may be applicable in cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE).  
• Note: For SAEs, this term is only applicable if the subject has completed the follow-up 
period and is expected to recover. 
• Recovered/resolved with sequelae:  The subject has recovered from the condition but with 
lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE criterion, the AE must be reported as an SAE. 
• Not recovered/not resolved:  The condition of the subject has not improved, and the 
symptoms are unchanged, or the outcome is not known.  Note: This term may be applicable in cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE).  
• Fatal:  This term is only applicable if the subject died from a condition related to the reported 
AE. Outcomes of other reported AEs in a subject before he/she died should be assessed as “recovered/resolved”, “recovering/resolving”, “recovered/resolved with sequelae” or “not recovered/not resolved”. An AE with a fatal outcome must be reported as an SAE. 
• Unknown:  This term is only applicable if the subject is lost to follow -up. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124097] of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_18044]/or causality of the AE or SAE as fully as possible (e.g. severe hypersensitivity reactions). This may include additional laboratory tests (e.g. skin prick test) or investigations, histopathological examinations, or consultation with other health care professionals. 
If a subject dies during participation in the trial or during a recognised follow-up period, Novo Nordisk may request a copy of the autopsy report including histopathology.  
New or updated information will be recorded in the CRF.  
 
10.3.5 Reporting of SAEs 
SAE reporting via electronic CRF  
• Relevant forms (AE and safety information form) must be completed in the CRF.   
• For reporting and sign- off timelines, see Figure 10-1 . 
• If the CRF is unavailable for more than 24 hours, then the site will use the paper AE form, 
and if the CRF is unavailable for more than 5 calendar days, then the site will use the paper 
safety information form (see box below).  
• The site will enter the SAE data into the C RF as soon as it becomes available.  
• After the trial is completed, the trial database will be locked, and the CRF will be 
decommissioned to prevent the entry of new data or changes to existing data. If a site receives a report of a new SAE from a subject or receives updated data on a previous ly 
reported SAE after CRF decommission, then the site can report this information on a paper 
AE and safety information form (see box below) or to Novo Nordisk  by [CONTACT_756].  
 
AE and SAE reporting via paper CRF  
• Relevant CRF forms (AE and safety information  form)  must be forwarded to Novo Nordisk 
in accordance with  Section 10.1.5 . 
• For SAEs, initial notification via telephone is acceptable, although it does not replace the 
need for the investigator to complete the AE and safety information form  within the 
designated rep orting timelines (as illustrated in Figure  10-1 ): 
• AE form within 24 hours 
• Safety information form within 5 calendar days 
• Both forms must be signed within [ADDRESS_124098] knowledge by [CONTACT_1275]. 
• The specific event form for AEs requiring additional data collection within 14  calendar days  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124099] details for SAE reporting can be found in the investigator trial master file. 
Reporting of AEs for non -Novo Nordisk medical devices provided by [CONTACT_3454] f or use 
in the trial  
Reporting of AEs on [COMPANY_002]  Accu check and Dexcom G6:  
All complaints (including AEs) should be reported directly to the manufacturer .  
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  78 of 100 
 
10.4 Appendix 4: Contraceptive guidance and collection of pregnancy information 
Definitions  
Woman of childbearing potential (WOCBP) 
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile.  If fertility is unclear and a menstrual cycle cannot be confirmed before first 
dose of trial treatment, additional evaluation should be considered. 
Females in the following categories are not considered WOCBP  
1. Premenarcheal  
2. Females with one or more of the following: 
• Documented total hysterectomy 
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy 
Females with permanent infertility due to an alternate medical cause other than the above (e.g. 
Müllerian agenesis, androgen insensitivity), investigator discretion should be applied in determining 
trial enrolment.  
3. Postmen opausal female:  
• A postmenopausal state is defined as amenorrhoea for 12 months without an alternative medical 
cause.  
• Females  ≥ 50 years of age can be considered postmenopausal (irrespective of treatment with a 
hormonal contraception or hormone replacement therapy (HRT)) if they have both: 
o Amenorrhoea and 
o Documentation of 2 high follicle stimulating hormone (FSH) measurements in the 
postmenopausal range and one of these was observed ≥1 year prior to screening. 
• Females ≥ [ADDRESS_124100] an acceptable effective contraception methods as described in 
Table 10-3 . 
Note: Documentation regarding categories 1 -3 can come from the site staff’s review of subject’s 
medical records, medical examination or medical history interview . 
Contraceptio n guidance  
Male subjects   
No contraception measures are required as the risk of teratogenicity/fetotoxicity caused by [CONTACT_111431]
32. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124101] an 
acceptable effective methods of contraception consistently and correctly as described in Table 10-3 . 
As a minimum, contraception should be maintained until treatment discontinuation33. 
Table 10-3 Acceptable contraceptive methods  
CONTRACEPTIVESa ALLOWED DURING THE TRIAL INCLUDE:  
ACCEPTABLE METHODSb 
• Progestogen -only oral hormonal contraception where inhibition of ovulation is not the primary 
mode of action 
• Male or female condom with or without spermicidec 
• Cervical cap, diaphragm, or sponge with spermicide 
• A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).  
NOTES  
a) Contraceptive use by [CONTACT_111432]. 
b) Considered effective, but not highly effective - failure rate of ≥1% per year. Periodic abstinence (calendar, symptothermal, post-
ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception. 
c) Male condom and female condom should not be used together (due to risk of failure with friction).  
 
Pregnancy testing  
• Additional pregnancy testing should be performed during the treatment period, if required 
locally . Please refer to the Appendix 9 (Section 10.9 ). 
• WOCBP should only be included after a negative highly sensitive urine pregnancy test (refer to 
Appendix 2 ( Section 10.2) and the trial flowchart ( Section 1.2). 
• As a minimum,  pregnancy test should be performed at the end of relevant systemic exposure 
(refer to Appendix 2 and the trial flowchart). 
• Pregnancy testing should be performed whenever a menstruation is missed or when pregnancy 
is otherwise suspected.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  80 of 100 
 
Collection of pregnancy information  
Female subjects who become pregnant  
• Investigator will collect pregnancy information on any female subject who becomes pregnant 
while participating in this trial.  
• Information will be recorded on the appropriate form and submitted to Novo Nordisk within [ADDRESS_124102]’s pregnancy (see Figure 10-2 ). 
• Subject will be followed to determine the outcome of the pregnancy. The investigators will 
collect follow -up information on subject and neonate which will be forwarded to Novo 
Nordisk within 14 calendar days. Generally, follow-up will not be required for longer than 1 
month beyond the delivery date. 
• Any termination of pregnancy will be reported. regardless of the foetal status (presence or 
absence of anomalies) or indication for procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any adverse event in connection 
with pregnancy or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. If relevant, consider adding “gestational”, “pregnancy related” or similar term 
when reporting the AE/SAE. 
• Pregnancy outcome should be documented in the subject’s medical record. Abnormal 
pregnancy outcome (e.g. spontaneous abortion, foetal death, stillbirth, congenital anomalies 
and ectopic pregnancy) is considered an SAE. 
• Any SAE occurring as a result of a post-trial pregnancy which is considered possible/probably 
related to the IMP by [CONTACT_111433] 3 (Section 10.3
) . While the investigator is not obligated to actively seek this 
information in former subjects, he/she may learn of an SAE through spontaneous reporting. 
Maternal f orm 1b  
≤ 14 calendar days after birthMaternal f orm 1a
≤ 14 calendar daysAfter birth/
termination 
of pregnancy
No additional 
action Normal outcome Maternal f orm 2 ≤ 14 calendar days
Paternal form*1 ≤ 14 calendar days Abnormal outcome 
Pregnancy 
verified
*1 Further information collected on Paternal form for male partners of 
female subjects requires signing of specific informed consent.
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Figure 10.1.Prior to 
birth or 
pregnancy 
termination For female subjects
 
Figure 10-[ADDRESS_124103] who becomes pregnant while participating in the trial will discontinue IMP . 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  81 of 100 
 
10.5 Appendix 5: Technical complaints: Definition and procedures for recording, 
evaluation, follow- up and reporting  
10.5.1 Definition of technical complaint  
Technical complaint definition  
• A technical complaint  is any written, electronic or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE but 
does not concern the AE itself.  
Examples of technical complaints:  
• Problems with the physical or chemical appearance of trial products (e.g. discoloration, 
particles or contamination) 
• Problems with packaging material including labelling  
• Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen-injector and the needle)  
Time period for detecting technical complaints  
All technical complaints  which occur from the time of receipt of the product at site until the time 
of the last usage of the product must be collected for products predefined on the technical 
complaint form.  
 
10.5.[ADDRESS_124104] be reported on a separate technical complaint form:  
1. One technical complaint form must be completed for each affected DUN.  
2. If DUN is not available, a technical complaint form for each batch, code or lot number must 
be completed.  
 
Timelines for reporting of technical complaints to Novo Nordisk  
The investigator must complete the technical complaint form in the CRF within:  
• 24 hours if related to an SAE  
• [ADDRESS_124105] enter the information on the technical complaint 
form in the CRF.  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124106].  
 
10.5.3 Reporting of technical complaints 
Reporting of technical complaints for Novo Nordisk products not included in technical 
complaint form  
Technical complaints on Novo Nordisk products not included in the technical complaint form 
should be reported to local Novo Nordisk . 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  83 of 100 
 
10.6 Appendix 6: Retention of human biosamples  
Hypersensitivity reaction samples  
In case of a systemic hypersensitivity reaction, the additional blood samples taken in relation to the 
reaction ( Section  8.9.2 ) may be retained to follow-up on the hypersensitivity reaction. If deemed 
relevant by [CONTACT_3454], relevant exploratory tests may be performed, e.g. histamine release 
(basophil activation). If measured, such data will be reported in a separate report. 
The samples will be stored at Novo Nordisk or a Novo Nordisk designated referral central bio-repository. The samples might be transferred to other countries, if not prohibited by [CONTACT_13125]. Only Novo Nordisk staff and bio-repository personnel will have access to the stored 
samples.  The samples may be shipped to a contract research organisation (CRO) for analysis. 
The samples will be anonymised (identified only by a unique sample ID, visit number, trial identification number and sampling date). Confidentiality and personal data protection will be 
ensured during storage after the end of trial and no direct identification of the subject  will be stored 
together with the samples.  
Potential further analyses of the samples will not have any consequences for the subject and their 
relatives. Subjects can contact [CONTACT_111434]. 
The samples w ill be stored after end of trial and until marketing authorisation approval or until the 
research project terminates, but no longer than [ADDRESS_124107] terminates, but no longer than 15 years from end of trial after which they 
will be destroyed. 
Metabolism samples (PK samples)  
Sample s for metabolism analysis may be retained for later analysis of metabolites if needed. If 
samples are selected for metabolite analysis, they will be stored at Novo Nordisk after end of trial 
and until marketing authorisation approval or until the research project terminates, but no longer 
than 15 years from end of trial after which they will be destroyed. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  84 of 100 
 
10.7 Appendix 7: Hypoglycaemic epi[INVESTIGATOR_111377] 10-4 Classification of hypoglycaemia 
Classification of hypoglycaemia  
Level  Glycaemic criteria  Description  
Hypoglycaemia alert value 
(level 1)  < 3.9 mmol/L (70 mg/dL) and  
≥ 3.0 mmol/L (54 mg/dL)  Sufficiently low for treatment with fast -acting 
carbohydrate and dose adjustment of glucose -lowering 
therapy  
Clinically significant 
hypoglycaemia (level 2)  < 3.0 mmol/L (54 mg/dL)  Sufficiently low to indicate serious, clinically important 
hypoglycaemia  
Severe hypoglycaemia 
(level 3)  No specific glucose threshold  1Hypoglycaemia associated with severe cognitive 
impairment requiring external assistance for recovery  
Notes: The Novo Nordisk terms are adapted from IHSG34, ADA35, ISPAD36, type [ADDRESS_124108] is the responsibility of the 
investigator and the titration guidelines can be overruled at his/her discretion35.  
Nocturnal hypoglycaemia Nocturnal hypoglycaemic epi[INVESTIGATOR_1841]: epi[INVESTIGATOR_111378] 00:01 and 05:59 both inclusive. 
Reporting of hypoglycaemic epi[INVESTIGATOR_111379] (PG) should always be measured by [CONTACT_111435][INVESTIGATOR_111380].  
The following should be reported in the eDiary as hypoglycaemic events: 
- PG values < 3.9 mmol/L (70 mg/dL) 
- Severe hy poglycaemic epi[INVESTIGATOR_111381]. Confirmation of the 
hypoglycaemic epi[INVESTIGATOR_111382]. In case a subject is not able 
to fill in  the eDiary (e.g. in case of hospi[INVESTIGATOR_11956]) at time of epi[INVESTIGATOR_1865], the subject can report the 
epi[INVESTIGATOR_111383]. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124109] is recommended to measure PG every 15 minutes until the PG value is ≥ 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved in 
accordance with current guidelines
38. 
Repeated low PG measurements can be reported by [CONTACT_111436][INVESTIGATOR_41106] a succeeding PG value is ≥ 3.9 mmol/L (70 mg/dL). In case of several low PG values within the 
hypoglycaemic epi[INVESTIGATOR_1865], the lowest value is the one that will be reported as the PG value for the 
hypoglycaemic epi[INVESTIGATOR_1865], but the start time of the epi[INVESTIGATOR_111384]. The remaining values will be kept as source data. 
If the severity of a hypoglycaemic epi[INVESTIGATOR_111385], only one hypoglycaemic epi[INVESTIGATOR_111386], reflecting the most severe degree of hypoglycaemia. 
Regarding the question: “To feel better, did you need help to get a sugary drink, food, or 
medicine?” the investigator must instruct the subjects to answer “Yes”, if the epi[INVESTIGATOR_111387], glucagon, or take 
other corrective actions. PG concentrations may not be available during an event, but neurological 
recovery following the return of PG to normal is considered sufficient evidence that the event was 
induced by a low PG concentration
38. 
eDiary  review  
At each contact [CONTACT_111437][INVESTIGATOR_1841]. In case of incomplete or incorrect data in the eDiary, the subject must be questioned whether there have been any severe hypoglycaemic epi[INVESTIGATOR_111388]. The 
subject shall update the reported data in the eDiary accordingly.  
Re-training of subjects  
The subject must be re-trained in how to report hypoglycaemic epi[INVESTIGATOR_111389]. The training should be documented by [CONTACT_111438]. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  86 of 100 
 
10.8 Appendix 8: Titration guideline  
Introduction 
Titration guidelines have been developed, providing recommended dose adjustments at different PG 
levels to ensure that subjects receive an optimal treatment. However, it is recognised that insulin 
treatment should be individualised, and the specific titration algorithms may not be applicable in 
certain clinical situations. Hence, it is important that other information, such as symptoms of hypo-
/hyperglycaemia, previous response to dose adjustments, other glucose measurements and other 
indicators of the subject’s level of glycaemic control, is taken into consideration when decisions on 
dosing are made. The investigator is responsible for the treatment of the subjects and can therefore 
overrule the guidelines to avoid safety hazards. 
Initiation of trial products  
At randomisation eligible subjects will be randomised to receive insulin icodec o r insulin degludec. 
• Insulin icodec  should be taken once weekly on the same day of the week. All subjects  should 
receive a loading dose at randomisation (V2), which consist of total daily basal insulin dose 
before randomisation x 7 + 50% of their total daily basal insulin dose x 7. The following 
weekly dose (V3) should be the total daily dose x 7. In the following table the weekly V2 and 
V3 doses for subjects receiving from 10U to 100U per day have been calculated. Please, note 
that the displayed values are round off to the nearest dose that is dividable by 10. 
 
Total daily dose 
before randomisation 
(U) V2 insulin icodec dose 
(U) V3 insulin icodec dose 
(U) Total daily dose 
before randomisation 
(U) V2 insulin icodec dose 
(U) V3 insulin icodec dose 
(U) 
10 110 70 56 590 390 
11 120 80 57 600 400 
12 130 80 58 610 410 
13 140 90 59 620 410 
14 150 100 60 630 420 
15 160 110 61 640 430 
16 170 110 62 650 430 
17 180 120 63 660 440 
18 190 130 64 670 450 
19 200 130 65 682 460 
20 210 140 66 690 460 
21 220 150 67 700 470 
22 230 150 68 710 480 
23 240 160 69 720 480 
24 250 170 70 740 490 
25 260 180 71 750 500 
26 270 180 72 760 500 
27 280 190 73 770 510 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  87 of 100 
 
28 290 200 74 780 520 
29 300 200 75 790 530 
30 320 210 76 800 530 
31 330 220 77 810 540 
32 340 220 78 820 550 
33 350 230 79 830 550 
34 360 240 80 840 560 
35 370 250 81 850 570 
36 380 250 82 860 570 
37 390 260 83 870 580 
38 400 270 84 880 590 
39 410 270 85 890 600 
40 420 280 86 900 600 
41 430 290 87 910 610 
42 440 290 88 920 620 
43 450 300 89 930 620 
44 460 310 90 950 630 
45 470 320 91 960 640 
46 480 320 92 970 640 
47 490 330 93 980 650 
48 500 340 94 990 660 
49 510 340 95 1000 670 
50 530 350 96 1010 670 
51 540 360 97 1020 680 
52 550 360 98 1030 690 
53 560 370 99 1040 690 
54 570 [PHONE_2545] 700 
55 580 390    
• Insulin degludec  should be taken once daily anytime of the day the same time every day. 
Switching from previous basal insulin should be in accordance with local label. 
• The treat -to-target approach will be applied to both treatment arms to optimise glycaemic 
control throughout the trial. 
• There are no maximum or minimum insulin doses.  
Dose adjustment of trial products during the trial  
After randomisation the investigator should adjust the trial products once weekly in connection with 
the scheduled visits/phone contacts as described below.  
• The dose adjustment will be based on the three pre- breakfast SMPG values measured on two 
days prior to titration and on the day of the contact. 
• If one or more SMPG values are missing, the dose adjustment should be performed on the 
remaining SMPG value(s). 
• The prescribed dose should be determined by [CONTACT_111439]. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124110] SMPG  Dose adjustment  
Value to use  mmol/L  mg/dL  U 
Lowest of the SMPG values  <4.4 <80 –3 
Mean of the SMPG values  4.4–7.2 80–130 0 
>7.2 >130  +[ADDRESS_124111] SMPG  Dose adjustment  
Value to use  mmol/L  mg/dL  U 
Lowest of the SMPG values  <4.4 <80 –20 
Mean of the SMPG values  4.4–7.2 80–130 0 
>7.2 >130  +[ADDRESS_124112] insulin doses is based on all relevant information. A reason for deviating from the algorithm 
should be entered the into the HCP web portal by [CONTACT_41192]. 
Missing insulin icodec dose guidance:  
If an insulin icodec dose is missed for ≤ [ADDRESS_124113] 
the planned dose as soon as possible and perform control SMPG measurement. If the missing dose 
is missed for > [ADDRESS_124114] should await the next planned day-of-injection. 
Dose recommendation from end of treatment and during follow up (insulin icodec)  
If it is decided that the individual subject should continue basal insulin after end of treatment, it is 
recommended that the subject is switched from insulin icodec to any available basal insulin at the 
discretion of the investigator. The investigator should instruct the subject in how to switch at the 
“end of treatment” visit (V28).  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124115]-trial basal insulin the following should be 
considered: 
• Calculate the new daily basal insulin dose dividing the latest insulin icodec dose by 7 
• Initiate the new daily basal insulin two weeks after the last injection of insulin icodec  
• Continue to measure pre-breakfast SMPG daily in the follow up period. If pre- breakfast SMPG 
exceeds 10.0 mmol/L (180 mg/dL), it should be considered t o initiate the daily basal insulin 
dose earlier than two weeks after the last dose of insulin icodec 
• Consider titrating the basal insulin once or twice weekly according to the pre- breakfast SMPG 
values and the local label of the chosen insulin. 
Data collec tion 
The subject should be instructed to report the following in the eDiary: 
• Date, dose and time of insulin degludec or insulin icodec injections 
• Ensure transfer of SMPG values with an indication of “pre- breakfast” or “other” ( Section 8.1.1 ) 
• Hypoglycaemic epi[INVESTIGATOR_111390] 7 (Section 10.7 ). 
While using the HCP web portal for titration the following will be entered by [CONTACT_1697]: 
• Insulin degludec or insulin icodec doses prescribed at this contact. 
• Reasons for deviation from the titration algorithms, if applicable. 
Data surveillance 
Surveillance of titration d ata will be performed centrally by [CONTACT_111440], if 
possible, a blinded manner. The data will be reviewed and significant deviations from the titration 
algorithm will be followed up.  
It is important that data regarding dose titration is entered into the eDiary and into the HCP web 
portal. Timely registration is crucial in order to take appropriate actions before the subject’s next 
site visit/phone contact. The aim is to reduce the time periods in which a subject may receive 
suboptimal treatment.  
The titration data should be reviewed by [CONTACT_41194] 24 hours (on workdays). The reviewer may contact [CONTACT_41195] e-mail or phone to clarify reasons for deviation or to 
request entry of missing data. When the investigator receives an inquiry, a response should be 
received at Novo Nordisk within 24 hours (on workdays). 
In addition, Novo Nordisk will monitor changes in HbA
1c. Novo Nordisk may visit or phone sites to 
discuss progress in glycaemic control and titration of individual subj ects. 
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  90 of 100 
 
10.9 Appendix 9: Country -specific requirements  
For Bulgaria: 
• Trial governance considerations : According to Regulation 31 (for defining the rules of 
Good Clinical Practice, 12 Aug 2007), art. 4, par. (2) - The protocol is prepared according to 
the requirements of GCP and contains as a minimum the following: 1) assessment of the 
expected benefits and risks; 2) definition of inclusion and exclusion criteria; 3) rationale for 
trial population, especially when it is expected to include subject s that cannot consent 
personally and other vulnerable groups; 4) description of the procedures for recruiting subject s and getting informed consent when it is expected to include subject s who are 
temporarily or constantly unable to consent personally and when it is expected to receive 
consent from an independent witness; 5) description of the plan and the procedure s for 
assuring complementary medical cares for the participants after the trial is ended; 6) monitoring procedures; 7) publication policy. 
For Japan:  
• Inclusion criteria 3 : age ≥ 20 years at the time of signing informed consent 
• Preparation/Handling/Storage/Accountability: The head of the trial site or the trial product 
storage manager assigned by [CONTACT_111441] (a pharmacist in principle) is 
responsible for control and accountability of the trial products. 
• Trial governance consideration : A seal is accepted as signature.  
• Exclusion criteria  4: the footnote, “ Simultaneous participation in a trial with the primary 
objective of evaluating an approved or non-approved investigational medicinal product for 
prevention or t reatment of COVID -[ADDRESS_124116] has been received more than 30 days before screening ”, is not applicable for Japan.  
• Discontinuation criteria  4, Section  7.1
: the footnote, “ Simultaneous participation in a trial 
with the primary objective of evaluating an approved or non-approved investigational 
medicinal product for prevention or treatment of COVID-[ADDRESS_124117]”, is 
not applicable for Japan. 
For Poland:  
• Indemnity statement: Novo Nordisk carries liability for the Trial exclusively in the scope 
defined by [CONTACT_111442] 6 September 2001 (uniform version Journal of Laws of 2008 No. 45 item 271 
with amendments). In order to support potential claims for liability attributable to the Trial, 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  91 of 100 
 
Novo Nordisk and Investigator are covered by [CONTACT_111443].  
For US:  
• Financial disclosure: Verification  under disclosures per Code of Federal Regulations 
(CFR) of Financial Conflict of Interest.  
For [LOCATION_013] : 
• Demography: Subject’s full Date of Birth is not allowed to be collected and must be 
shortened to Year of Birth in CRF.  
• Contraception requirements:  Contraception requirements as per CTFG guideline. 
• Exclusion criteria  4: the footnote, “ Simultaneous participation in a trial with the primary 
objective of evaluating an approved or non-approved investigational medicinal product for prevention or treatment of COVID -[ADDRESS_124118] has been received more than 30 days 
before screening ”, is not applicable for [LOCATION_013] . 
• Discontinuation criteria 4, Section  7.1
: the footnote, “Simultaneous participation in a trial 
with the primary objective of evaluating an approved or non-approved investigational medicinal product for prevention or treatment of COVID-[ADDRESS_124119]”, is 
not applicable for [LOCATION_013] . 
 
For Ukraine where CGM is not approved at the time of the final protocol version 1.0: 
• The CGM is regarded as an investigational device and will be labelled to indicate  for 
investigational use only. The CGM has been selected in order to provide the best data 
accuracy and to be consistent in the global clinical programme.  
Technical complaints on the CGM must be reported to  on a special technical 
complaint paper form. 
Timelines for reporting, fro m the trial site obtaining knowledge of the technical complaint: 
o Technical complaint assessed as related to a SAE within [ADDRESS_124120] be collected by [CONTACT_093].  
CONFIDENTIAL
VV-CLIN-135991 1.0 .

Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124121] vigilance procedures. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  93 of 100 
 
10.10 Appendix 10: Abbreviations  
AE adverse event  
ANCOVA  analysis of covariance  
BG blood glucose  
CGM  continuous glucose monitoring  
CI confidence interval  
CRF  case report form  
DPP-[ADDRESS_124122]  
FPG fasting plasma glucose  
GCP  Good Clinical Practice  
GLP -1 RA glucagon -like peptide 1 receptor agonists  
HbA 1c glycated haemoglobin  
HCP  healthcare professional  
HRT  hormone replacement therapy  
IB investigator’s  brochure  
ICH International Council for Harmonisation  
IEC independent ethics committee  
IgE immunoglobulin E  
IMP investigational medicinal product  
INN international nonproprietary name  
[CONTACT_111447] -WOB  last available planned on -treatment without initiation of more than 2 weeks bolus insulin treatment  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124123] characteristics  
SMPG  self-measured plasma glucose  
T1D type 1 diabetes  mellitus  
T2D type 2 diabetes mellitus  
V visit 
WOCBP  woman of child bearing potential  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  95 of 100 
 
10.11 Appendix 1 1: Protocol amendment history  
The Protocol amendment summary of changes table for the current protocol version is located 
directly before the table of contents. 
Protocol version 2.0 (30 November 2020) 
This amendment is considered to be non-substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union1, because 
it neither significantly impacts the safety nor physical/mental integrity of subjects nor the scientific value of the trial.  
Overall rationale for preparing protocol, version 2.0: 
The protocol has been amended to allow subjects to co- participate in clinical trials evaluating 
medicinal products for prevention or treatment of COVID- 19 disease o r postinfectious conditions.  
Section # and name  [CONTACT_111448].  Disclose version history.  
1.2 Flowchart  “(insulin icodec serum 
concentration) ” and “(anti -insulin 
icodec antibodies)” have been added.  To make it clear that PK and antibody 
testing are only conducted in the 
insulin icodec arm.  
1.2 Flowchart  Deleted randomisation visit ”X” for 
hypo -reporting.  Correction of error (hypo -reporting 
should follow AE reporting).  
2.3.1 Risk assessment  Added a further COVID -19 related 
mitigation strategy . To provide guidance in case of 
COVID- 19 related lock down of a site 
or country.  
4.1 Overall design  Rephrasing to “ both with or without 
non-insulin anti -diabetic drugs .” For alignment with protocol title and 
inclusion criteria.  
5.[ADDRESS_124124].  
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  96 of 100 
 
Section # and name  [CONTACT_111444]  
7.[ADDRESS_124125] 
discontinuation/withdrawal from the 
trial Updated wording to “treatment status 
session”.  Correction of error.  
8.3 Adverse events (AEs) and serious 
adverse events (SAE)  Footnote to table [ADDRESS_124126] all cerebrovascular events event though the EAC will only be 
confirming stroke.  
8.1.3 Clinical outcome assessments  Added DPEM and IPQ version 
numbers.  Version numbers are required.  
8.1.3 Clinical outcome assessments  Deleted “ The scoring mechanism is 
currently being developed. ” Not required for the analysis.  
8.1.[ADDRESS_124127] . 
8.5 Pharmacokinetics  “for subjects randomised to insulin 
icodec” has been added.  To make it clear that PK testing is 
only conducted in the insulin icodec 
arm. 
8.5 Pharmacokinetics  Rephrasing to: The date and exact 
clock time for blood sampling must be 
recorded.  The date and exact clock time of the 
sampling must be recorded in the lab 
requisition form, not in the eCRF.  
8.9.1 Anti -drug antibodies  “for subjects randomised to insulin 
icodec” has been added.  To make it clear that anti -drug 
antibodies testing is only conducted in 
the insulin icodec arm.  
8.9.2 Hypersensitivity  The sentence “For the subjects 
randomised to insulin icodec” has 
been added in the first paragraph.  To clarify that the additional blood 
sampling is only taken in the insulin 
icodec arm.  
[IP_ADDRESS] Monitoring  Deleted “HCP web portal” and 
“eDiaries and electronic patient 
reported outcomes through the web 
portal”.   Monitors are not requested to perform 
source data verification in the HCP web portal . 
10.9 Appendix 9 Country -specific 
requirements  Added [LOCATION_013]  specific demography 
collection and contraception 
requirements.  [LOCATION_013] specific requirement s. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  97 of 100 
 
Section # and name  [CONTACT_111444]  
10.9 Appendix 9: Country/Region -
specific requirements  Deleted [LOCATION_003] specific eye 
examination requirement,  
and added [LOCATION_003] specific financial 
disclosure.  [LOCATION_003] will follow the global 
requirements for eye examination in 
section 8.2.5 , 
and correction of missing informa tion. 
10.11  Appendix 11: Protocol 
amendment history  New appendix added.  Log amendments and version history.  
 
 
 
 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  98 of 100 
 
11 References  
1. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_124128] of clinical trials on medicinal products for human use. 2001. 
2. American Diabetes Association. 2. Classification and Diagnosis of Diabetes:. Diabetes Care. 2019;42(Suppl 1):S13-S28. 
3. International Diabetes Federation. IDF Diabetes Atlas, 9th Edition. 2019. 4. Alatorre C, Fernández Lan dó L, Yu M, Brown K, Montejano L, Juneau P, et al. Treatment 
patterns in patients with type 2 diabetes mellitus treated with glucagon -like peptide -1 
receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide an d liraglutide. Diabetes Obes Metab. 2017;19(7):953-61. 
5. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res. 2005;36(3):197-209. 6. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 
2004;88(4):787-835, ix. 
7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes, 2015: a patient- centred approach. 
Update to a position statement of the American Diabetes Association and the European Associatio n for the Study of Diabetes. Diabetologia. 2015;58(3):429-42. 
8. European Medicines Agency. Guideline on clinical investigation of medicinal products in 
the treatment or prevention of diabetes mellitus (CPMP/EWP/1080/00 Rev. 2). 29 Jan 2018. 
9. Halimi S, B alkau B. Better analyze the determinants of therapeutic inertia to overcome it. 
Diabetes Metab. 2012;[ADDRESS_124129] 3:S27-8. 
10. Khunti K, Millar -Jones D. Clinical inertia to insulin initiation and intensification in the [LOCATION_006]: 
A focused literature review. Prim Car e Diabetes. 2017;11(1):3-12. 
11. Novo Nordisk A/S. Investigator's Brochure, insulin icodec, project NN1436, (edition 6). 5 
Jun 2020. 
12. Novo Nordisk A/S. Investigator's Brochure, Insulin Degludec (Tresiba®),
 project : NN1250 
IDeg, (edition 15). 2018. 
13. Novo Nordisk A/S. Tresiba® (insulin degludec) EU Summary of Product Characteristics 
(SmPC). 12 Nov 2018. 
14. Novo Nordisk A/S. Tresiba® (insulin degludec), US Prescribing Information (PI). Mar 2018. 
15. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once- weekly 
medications for diabetes. Diabetes Obesity & Metabolism. 2011;13(2):144-9. 
16. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic 
Kidney Disease. http://www.kidney-international.org. 2013 2013. 
17. Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ. Assessment and management of 
hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2009;[ADDRESS_124130] 12:134-45. 
18. Food and Drug Administration, CDER. Guidance for Industry. Diabetes Mellitus: 
Developi[INVESTIGATOR_111391], Draft Guidance. February 2008. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_124131] of adding 
insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with 
metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP -1 Study). Diabetes Obes Metab. 2016;18(7):663-70. 
20. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeV ries JH, et al. International 
Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-40. 
21. Little R, Rubin D. Statistical analysis with missing data. Sons. JW, editor. [LOCATION_001].: John 
Wiley & Sons. 1987. 
22. World Medical Asso ciation. WMA Declaration of Helsinki - Ethical Principles for Medical 
Research Involving Human Subjects. Last amended by [CONTACT_941] 64th WMA General Assembly, Fortaleza, Brazil. October 2013. 
23. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Pr actice E6(R2),  Step 4 
version. 09 Nov 2016. 
24. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351(12):1250-1. 
25. U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007 as amended by [CONTACT_43679] "Clinical Trials Registration and Results Information Submission". 21 September 2016. 
26. The E uropean Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, article 57. 30 April 2004. 
27. The European Parliament and the Council of the European Council. Regulation (EC) No 
1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, article 41. Official Journal of the European Communities. [ADDRESS_124132], 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version available at www.icmje.org . 
29. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et 
al. Second symposium on the definition and management of anaphylaxis: summary report --
Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391-7. 
30. Kemp S F, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin 
Immunol. 2002;110(3):341-8. 
31. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised 
nomenclature for allergy for global use: Report of the Nomenclat ure Review Committee of 
the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6. 
32. Scialli AR, Bailey G, Beyer BK, Bøgh IB, Breslin WJ, Chen CL, et al. Potential seminal 
transport of pharmaceuticals to the conceptus. Reprod Toxicol. 2015;58:213-21. 
33. Clinical Trial Facilitation Group (CTFG), Heads of Medicines Agency. Recommendations 
related to contraception and pregnancy testing in clinical trials. 21 Sep 2020. 
CONFIDENTIAL
VV-CLIN-135991 1.0 .
Protocol  
CONFIDENTIAL  Date:  14 April 2021  Novo Nordisk  
Trial ID: NN1436 -4478  Version:  3.0 
Status:  Final  
Page:  100 of 100 
34. International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0
mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of
the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care. 2017;40(1):155-7.
35. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care inDiabetes -2018. Diabetes Care. 2018;41(Suppl 1):S55-S64.
36. Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, et al. ISPAD
Clinical Practice Consensus Guidelines 2018: Assessment and management ofhypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2018;19 Suppl27:178-92.
37. Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, et al.
Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists,the American Association of Diabetes Educators, the American Diabetes Association, theEndocrine Society, JDRF International, The Leona M. and Harry B. Helmsley CharitableTrust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care.2017;40(12):1622-30.
38. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia
and diabetes: a report of a workgroup of the American Diabetes Association and theEndocrine Society. Diabetes Care. 2013;36(5):1384-95.
CONFIDENTIAL
VV-CLIN-135991 1.0 .